Teva woes keep piling up with another investigation for bribery


Teva is reportedly under investigation by police in Israel for bribing foreign officials.

When it rains it pours, and Teva is experiencing a flood of bad news of near biblical proportions. The same day that the company showed CEO Erez Vigodman the door, the drugmaker was said to be under investigation by Israeli police for bribing foreign officials in an investigation that mirrors charges it recently settled with U.S. authorities.

The company acknowledged to Haaretz that Israeli police are conducting a bribery investigation similar to the U.S. probe. Sources told Haaretz it centered on Teva paying hundreds of millions of dollars in bribes to foreign officials and then creating falsified documents to hide the payments.

That U.S. case concerned issues that had occurred between 2007 and 2013 in Russia, Mexico and Ukraine. The company agreed in December to pay nearly $520 million to the U.S. Department of Justice and Securities and Exchange Commission to resolve the violations of the Foreign Corrupt Practices Act. The criminal fine to the DOJ totaled more than $283 million, while Teva ponied up $236 million to the SEC.

The latest disclosure is among a mounting list of problems that has embroiled the company and cost Vigodman his job just 18 months after announcing its $40.5 billion deal for Allergan’s generics unit that many thought would be the big turnaround for the company. The problems started with the fact that it took Teva so long to close the Allergan deal that some investors had lost faith in its upside.

Just months after finally getting it closed last August, generics CEO Siggi Olafsson—a cheerleader for the deal—unexpectedly said he was leaving, spooking investors since he was considered essential to making it work. On top of that a tough pricing environment for the generics industry has left questions in investors minds about how Teva will untangle the mess.

As if in answer, the company told them in January the company was going to have to trim its sales guidance for 2017 by more than $1 billion.

Now with the company’s stock price down more than 50% from its August 2015 highs, Vigodman is out and Chairman Yitzhak Peterburg will handle the day-to-day CEO duties while a permanent replacement is sought. Director and Celgene vet Sol Barer will serve as chairman.

On Tuesday, though, one analyst saw something to like in the whole mess. Credit Suisse analyst Vamil Divan told investors in a note that the change at the top may allow for a fresh start.

“We believe the changes underscore the difficulties Teva has faced over the past 18 months and may be well received as investors look for fresh faces to lead a potential turnaround at the company,” Divan wrote.

Divan has some specific issues that he expects management to answer next week when Teva reports earnings. He wants to see if even the revised earnings projections will be walked back further in light of a court ruling late last month that tossed out four patents on long-acting multiple sclerosis star Copaxone, putting billions of dollars at risk. The analyst wants to know what this is going to do to Teva’s ability to pay down debt and what it will mean for the company’s dividend.

As he sees it, “It will be imperative for TEVA to bring in a CEO who understands the intricacies of the generics business but who can also work to bolster a specialty pharma business,” Divan wrote to clients.

thanks to: FiercePharma

Struggling Teva said to plan thousands of job cuts as it hunts for CEO


Changes are afoot at foundering Teva—and they include job cuts and a recruitment freeze.

Local media reports said Thursday that the Tel Aviv, Israel-based generics giant is looking at cutting up to 6,000 jobs. A company spokeswoman confirmed plans to reduce costs, but said Teva “does not have a headcount target” because the number of job cuts would depend on the “right-sizing of each individual area of our business.”

“As the company previously stated, we are looking to reduce costs in our business in every area, including, among other things, ending unprofitable activities and streamlining some activities and functions throughout the organization,” spokeswoman Denise Bradley said via email.

Israeli newspaper Calcalist had reported that the company already laid off 100 workers and was planning to pink-slip between 5,000 to 6,000 worldwide beginning after Passover in mid-April. In a statement seen by Reuters, Teva said it would be “freezing recruitment” and allowing attrition to reduce employment numbers.

The moves follow a vow from interim CEO Yitzhak Peterburg to “do what it takes” to protect the struggling company’s revenue guidance, “including additional cost reduction if necessary.” The expected revenue range of $23.8 billion to $24.5 billion has already been walked back once—by more than $1 billion—thanks, in part, to a massive slowdown in new product revenue.

Peterburg, who took the helm after former skipper Erez Vigodman’s abrupt February departure, has also pledged a review of Teva’s businesses, prompting split-up speculation from slim down-happy analysts.

“We will leave no stone unturned,” he told investors on a recent conference call, noting that “we are here to fix what is not working.”

These days at Teva, that’s a lot. The company has been suffering from pricing pressure that’s pummeled the generics industry across the board, but it has some unique problems, too.

For one, shareholders have maligned its recent dealmaking efforts—including an arguably too-expensive pickup of Allergan’s generics unit and a Mexican generics buy that went very, very sour. For another, the company has billions in sales at stake if copies of leading multiple sclerosis med Copaxone hit, and a judge’s January tossing of four key patents on the med only improved the likelihood of that scenario.

Those issues and others have taken a heavy toll on the company’s stock, which has sunk by more than 70% in the last 12 months.

The company said that any job cuts would be decided in concert with its workers.

“These processes are conducted through a continuous open dialogue with the employees,” a spokesperson said in a statement, noting that “this will be the practice” even in its home country of Israel, where workers in the past have promised to strike if layoffs hit.

thanks to: FiercePharma

Teva CEO Vigodman exits, piling uncertainty onto the struggling drugmaker


Teva CEO Erez Vigodman is stepping down, and company chairman Yitzhak Peterburg will take over as interim chief.

So long, Erez Vigodman. After a brutal 2016 and start to 2017 for Teva, the company’s CEO is stepping down.

The move, announced late Monday, comes as the result of a “mutual agreement” between Vigodman and Teva’s board, the drugmaker said. Teva Chairman Yitzhak Peterburg will take up the reins as interim CEO while Teva works with a search firm to tap a permanent replacement. Director and Celgene vet Sol Barer will serve as chairman.

Vigodman’s departure follows several months of turmoil at the Israeli pharma. Last year, it faced lengthy delays to its $40.5 billion pickup of Allergan’s generics unit, which investors weren’t all that keen on by the time it actually closed. Then, Teva’s buy of Mexico’s Rimsa went so awry that Rimsa’s founders sued the company. In December, generics CEO Siggi Olafsson—a big supporter of the Allergan deal—unexpectedly hit the road. A tough pricing environment for the generics industry was the icing on the cake.

And so far, 2017 hasn’t been much kinder. In January, Teva walked back its 2017 sales guidance by more than $1 billion, citing launches that hadn’t gone as planned. Inherited pay-for-delay penalties have taken their toll, and late last month, a court tossed out four patents on long-acting multiple sclerosis star Copaxone to put billions of dollars at risk.

While investors haven’t enjoyed the roller coaster—in October, shares hit a two-year low, and they’ve only gone south from there—“we believe that more investors will be uneasy with the uncertainty of an unexpected and abrupt CEO departure,” Wells Fargo analyst David Maris wrote in a Monday note to clients.

Evercore ISI analyst Umer Raffat has already heard feedback to that effect. “On average, investor reaction has been neutral to slightly negative,” he wrote in his own note Tuesday morning.

One influential shareholder who may not be too torn up over the change: Activist Benny Landa, who has lobbied for years for more pharma experience on Teva’s board.

“What was obvious to me in the past is now clear: the most suitable CEO is someone with a strong background in global pharma—ideally, a person who has managed a pharma company or was in a very senior position in a pharma company,” he told Israeli newspaper Globes.

But seasoned vets aren’t all Landa wants to see at the Petah Tikva-based company. The way he sees it, splitting Teva into two companies—one focused on generics, one on specialty meds—would ensure that “each company gets its fair share of the debt and cash in order to give each company its chance to take off.”

“Teva has recently focused on generics to the extent that it lost direction, and didn’t realize that it should invest in the innovative field for the sake of its future,” he said. “These are actually two sectors with almost no connection between them.”

thanks to: FiercePharma

Teva recalls 500,000 units of diabetes drug manufactured by Patheon



Teva has recalled 12 lots of Watson brand Glipizide manufactured by Patheon that didn’t meet specs for dissolution.

It is not as if Israeli drugmaker Teva didn’t already have enough on its plate, what with its CEO having been shown the door, a court overturning patents to its key moneymaker and investors getting restive. On top of that, it is having to recall nearly half a million units of a Type 2 diabetes drug that it picked up in its Actavis buyout.

The drugmaker is recalling 12 lots, comprising 499,320 units of 2.5-mg extended-release tablets of Glipizide, an oral rapid-and short-acting treatment for Type 2 diabetes. The problem is that the product missed dissolution specs at the 10-month testing period. As its letter to retailers points out, that could be a problem for people with diabetes because if the active ingredient is released too quickly then their blood sugars may rise.

The voluntary nationwide recall began Jan. 30. The drug is manufactured under the Watson Laboratories brand. It is actually made in a plant in Cincinnati, OH by contractor Patheon.

The drug is one Teva got in its $40.5 billion buyout of Actavis, the generics business of Allergan. That deal and the debt laid on top of Teva were among the brewing issues that led to Erez Vigodman’s departure this month. Vigodman’s exit came after months of turmoil at the Israeli pharma.

Last year, it faced lengthy delays to its $40.5 billion pickup of Allergan’s generics unit. Between that and a tough pricing environment in the U.S., by the time the deal closed, investors weren’t as revved up by it. Then in December, generics CEO Siggi Olafsson—a big supporter of the Allergan deal—unexpectedly left.

All of this leaves Teva looking for a new CEO and pondering its future, with some analysts wondering if it is time for the company to split itself apart. That is a possibility that might be made more difficult after a court recently upturned four patents on long-acting multiple sclerosis star Copaxone, putting billions of dollars of revenue at risk.

thanks to: FiercePharma


Teva faces billions in lost sales as court tosses four long-acting Copaxone patents



A U.S. Court has upturned four patents covering Teva’s long-acting version of MS star Copaxone.

It’s déjà vu for Teva Pharmaceutical in a bad, bad way.

Late Monday, the Israeli drugmaker confirmed that the U.S. District Court for the District of Delaware had upturned four of its patents on the long-acting version of multiple sclerosis star Copaxone, putting billions of dollars in revenue at risk.

It’s not an opening of the floodgates for generics makers, who have “several steps still to go” before they can challenge the MS behemoth, as Credit Suisse analyst Vamil Divan put it in a note to clients. Teva CEO Erez Vigodman, for his part, said in a statement that his company “would move forward with an immediate appeal,” and Divan expects the company to request a preliminary injunction preventing any generics from launching until the legal process surrounding all of Teva’s Copaxone IP is completely wrapped up.

Teva has sued its wannabe rivals on a fifth and sixth patent, too, and an inter partes review appeal is underway at the U.S. Patent and Trademark Office. And of course, if knockoffs are to roll out, they’ll need to win the FDA’s green light first.

Still, Divan doesn’t think it’ll be long before copycats show up. He expects a Novartis/Momenta Pharmaceuticals partnership “and potentially one other competitor to launch later this year and lead to pricing pressure on the brand,” the analyst wrote.

The Petah Tikva-based company has been here before. Back in 2013, a court upturned its patents on the original, 20 mg formulation of its star med, but Teva managed to convert most of its patients to the new-and-improved version before generics hit.

Now, though? There will be no backup med to turn to if Teva’s IP shield is struck down.

That’s not a good prospect for a company whose sales are already struggling. Earlier this month, Teva walked down its 2017 guidance by more than $1 billion after new 2016 launches failed to pan out. It now predicts a top-line haul of between $23.8 billion and $24.5 billion for the year, but some analysts—including Bernstein’s Ronny Gal—have found that figure hard to swallow.

It’s “a tough picture,” Gal wrote in early January.

thanks to: FiercePharma


Teva wraps up Cipro pay-for-delay suit inherited with Barr buy


by Eric Sagonowsky |



Teva agreed to a $225 million settlement on a long-standing class action suit brought by the purchasers of Bayer’s Cipro.

Shortly after paying $520 million to the feds to resolve bribery charges in a couple of markets outside of the U.S., Teva has agreed to deal terms to settle a lengthy class action lawsuit in California.

The Israeli pharma giant agreed to a $225 million settlement with a group that bought Bayer’s antibiotic Cipro, Reuters reports. The plaintiffs argued that alleged pay-for-delay deals from the 1990s between Bayer and Teva’s Barr Laboratories led to higher prices and violated antitrust law, according to the news service.

The plaintiffs brought the case against Barr in 2000. Eight years later, Teva picked up Barr for nearly $9 billion.

In a statement, a Teva spokesperson said the company “reached a settlement in the pending Cipro antitrust litigation that was inherited when Teva acquired Barr in 2008. Teva is pleased that this long-standing litigation has been resolved.”

California’s Supreme Court will need to sign off on the settlement, according to Reuters.

Teva’s deal comes on the heels of a separate pay-for-delay settlement between the FTC and Endo Pharmaceutical, reached just days ago. As authorities announced that arrangement, they said they’d continue to pursue a case against Watson and Allergan.

The new Teva agreement closely follows another move by the company to wrap up a legal issue with federal authorities: violations of the Foreign Corrupt Practices Act. Back in December, Teva agreed to a settlement worth nearly $520 million to resolve bribery charges in several markets. In that case, a criminal fine to the DOJ totaled more than $283 million, and Teva paid $236 million to the SEC.

Together, the two deals amount to nearly three-quarters of a billion dollars in payments in a matter of two months.

In the wake of that settlement, a shareholder went after the company, plus current and former execs, with a petition for approval of a derivative suit.

Despite its multiple recent settlements, Teva might not be out of the woods yet. It’s among a group being investigated by the DOJ for possible generics price collusion.

thanks to: FiercePharma



FDA cites ‘significant’ sterility concern at Teva injectables plant


The FDA has posted the warning letter that Teva recently acknowledged getting for its troubled sterile manufacturing plant in Hungary. The letter outlines concerns about sterility and contamination issues at the plant and gives the company a long list of marching orders that it says must be completed before the plant will be allowed to again ship product to the U.S.

Seven observations were listed in the letter including problems with contamination in media fills, a problem the FDA said “indicates a potentially significant sterility assurance problem” at the plant in Godollo that Teva opened in 2012 to expand its sterile manufacturing capacity. The plant is currently closed while Teva works on solving the problems inspectors first outlined in a Form 483 issued in January.

Among problems noted, inspectors said the plant did not adequately investigate media-fill contamination on aseptic manufacturing lines. It cited as an example a media-fill run performed in September of last year which resulted in 31 contaminated units.

It said employees did not identify the microorganisms found in the contaminated units. Identifying them is essential, the FDA said, because otherwise there is no way to sufficiently understand the potential sources and scope of the contamination, the report said.

The FDA criticized the plant for poor aseptic processing techniques including seeing an operator sitting on the clean-room floor during setup of the filling line but then not changing the gown being worn. Others leaned against clean-room walls.

Additionally, investigators said some colony counts for environmental and personnel monitoring did not match up with the plant’s official records. On top of that, there were “quality-related documents in a waste bin” that raised questions about record keeping. Stand-alone computer systems didn’t have controls like routine audit trail reviews and full data retention that would assure that analysts weren’t deleting data.

Teva acknowledged getting the letter two weeks ago and has said that it is working on the problems, addressing “both the specific concerns raised by investigators as well as the underlying causes of those concerns.”

Additionally, Teva said it is working to replenish critical and priority products as quickly as possible, “in some cases by transferring products to other Teva manufacturing sites and–as needed–by identifying alternate suppliers for products in short supply or out of stock.”

The saga at the Godollo site began in January when the FDA inspected the plant, issuing the Form 483. Teva suspended production to deal with the citations, but in May the FDA put the plant on its import alert list, banning all but two drugs: the cancer treatment bleomycin and antibiotic amikacin, which were exempted to avoid shortages. Teva has been recalling its other drugs produced at the facility.

In the letter posted this week, the FDA presented Teva with a list of its expectations, asking among other things for a comprehensive review of all sterility test positive and media-fill failure investigations since January 2014. It wants Teva to update its standard operating procedures and also to review video taken during production of in-date batches sent to the U.S. to figure out what might have caused the contamination.

thanks to: FiercePharma

UPDATED: Pii produced products recalled by Teva


Teva ($TEVA) is recalling nearly 43,000 bottles of paricalcitol, a drug used by dialysis patients. But in this case, Teva didn’t manufacture them. They were produced by Pharmaceutics International Inc., or Pii, a U.S. CMO that recently ran into problems with European regulators.

According to the most recent FDA Enforcement Report, Teva is recalling 42,969 bottles of paricalcitol in three dose sizes in 30-count bottles, 32,015 of 1 mcg bottles; 5,556 of 2 mcg bottles and 5,398 of 4 mcg bottles. Paricalcitol is used to treat and prevent overactive parathyroid glands in patients with chronic kidney disease who are on dialysis.

The voluntary recall, which began several weeks ago, was initiated because the products failed stability testing for impurity levels.

The paricalcitol, the FDA report says, was manufactured by Hunt Valley, MD-based Pii. Several months ago, the European Medicines Agency said it was pulling the manufacturing certification for the contract manufacturer after inspectors noted a number of problems. In the critical category was Pii’s failure to minimize the risk of cross-contamination between hazardous and non-hazardous products, the report said. Inspectors also noted the facility had an unqualified HPLC system and unacceptable approach to production equipment qualification.

In response, the company “brought in a team of experts” to address each area of concern and says it is giving the EMA’s action top priority.

While this recall falls on Pii, Teva is facing manufacturing concerns of its own. The FDA last week issued a warning letter to Teva’ sterile manufacturing plant in Hungary, a facility that earlier this year was banned from exporting most products to the U.S. Teva says it is conscientiously addressing the the FDA’s concerns and their underlying causes.

– access the recall report here

thanks to: FiercePharma

UPDATED: Teva’s struggling sterile plant hit with FDA warning letter


The regulatory quagmire has deepened for the Teva Pharmaceutical sterile injectables plant in Hungary which the FDA banned this year over slipshod manufacturing standards. The FDA has now issued the plant a warning letter.

In an SEC filing on Tuesday, Israeli-based Teva acknowledged receiving the warning letter the previous Friday, and for the first time gave some indication of the problem areas. It said the FDA “cited deficiencies in manufacturing operations and laboratory controls, and in the Company’s data integrity program.”

In an emailed statement today, Teva said it “has been using a systems-based approach with respect to our remediation efforts,” addressing both the FDA concerns and the underlying causes. “As a matter of practice, Teva manufactures according to the highest quality and compliance standards.”

The company also said it is working to resupply “critical and priority products as quickly as possible,” by bringing in products from other Teva manufacturing sites and finding other suppliers for products in short supply or out of stock.

The warning letter follows a series of other actions by the FDA, which first issued a Form 483 following a two-week inspection in January at the Godollo plant, a relatively new facility which the company opened in 2012 to expand its injected drug capacity. Teva suspended production to deal with the citations but the FDA in May put the plant on its import alert list, banning all but two drugs–the cancer treatment bleomycin and antibiotic amikacin, which were exempted to avoid shortages. Teva has been recalling from the market its other drugs produced at the facility.

The regulatory issues come when Teva has a lot on its plate. It is in the process of assimilating a huge portfolio of products, plants and employees it got in its $40.5 billion buyout of Allergan’s generics business, while selling off those parts of the business required by regulators to preserve competitive markets.

But Teva has suggested it may not be done with acquisitions to solidify its place as the largest maker of generic drugs, while also looking at moves in the branded market. Earlier this week, a Teva spokesperson said the company would consider opportunities in biosimilars, suggesting to some that Teva might look at buying South Korea’s Celltrion. Celltrion is trying to sell part of its business and the two have a relationship.

CEO Erez Vigodman has said the biosimilars are part of the company’s growth strategy but also said it will be on the hunt for “attractive specialty assets, or branded drug assets or pipeline assets” that fit in with the therapeutic areas it’s already tackling.

– read the filing

thanks to: FiercePharma

UPDATED: Teva recalling all lots of 4 drugs made at troubled Hungary plant


Teva continues to deal with the fallout from an FDA ban of its sterile injectables plant in Hungary and is now recalling all lots of four different injected drugs.

According to the most recent FDA Enforcement Report, the Teva Pharmaceutical ($TEVA) recall includes 92,480 containers of antibiotic linezolid; 14,661 vials of heart surgery drug eptifibatide; 13,223 vials of anti-nausea drug ondansetron and 1,299 bags of argatroban, used for treating heparin-related complications. The report says Teva began the recalls in June, although the FDA only last week gave them a class II designation.

The products all came out of Teva’a plant in Gödöllő, a relatively new facility which the company opened in 2012 to expand its injected drug capacity. The $110 million, 15,000-square-meter plant has 6 production lines and the capacity to churn out 160 million to 200 million units of injectable meds annually.

But those lines went idle earlier this year when Teva temporarily halted production following an FDA inspection in January that found a number of manufacturing issues. The FDA followed that up in late May when it issued an import alert for the facility, banning all but two essential products from the facility: cancer treatment bleomycin and antibiotic amikacin.

Teva in a statement today said it had begun recalling “all in-date lots” of the four in the US, “in order to ensure that disposition decisions for U.S. products manufactured at the Gödöllő site were in alignment with FDA’s import alert. In July, we recalled 7 lots of Amikacin for reasons unrelated to the import alert.  This was an extension of a previous recall that Teva initiated in March. We are working around the clock to re-start manufacturing operations in Godollo and expect that to occur in the coming months.”

Teva has not specified the nature of the observations laid out in an FDA Form 483, but said it was working closely with the FDA to resolve the issues and return supplies of its products. It said in some cases it would look for alternative sources of supply. None of the four drugs is currently listed on the FDA’s drug shortages list. Teva has said that it is unaware of any adverse events tied to any of the drugs shipped from the facility.

The plant issues arose at a tricky time for Teva, which was in the midst of trying to close on its $40.5 billion purchase of the generics unit of Allergan ($AGN). After delays and an agreement with the FTC that is would divest 75 products, the deal closed last month.

– access the recalls here

thanks to: FiercePharma

Teva issues another recall of antibiotics, this time from a Canadian plant

For the second time this year, Teva ($TEVA) has issued a recall of antibiotics produced at one of its facilities. This time it’s a plant in Canada.

In the most recent action, the company said it is recalling more than 53,000 bottles of amoxicillin manufactured by Teva Canada Limited in Toronto.

According to an FDA enforcement report, the nationwide voluntary recall of the antibiotic was initiated because it is considered a “superpotent drug” on the basis of an out of specification test result for assay during stability testing. The regulatory agency has classified the recall as a Class II event, which means there isn’t an immediate threat of death or danger from the product.

Earlier this year, the drugmaker began recalling amikacin sulfate from its facility in Hungary due to the potential for the presence of glass particulate, which the company  said could cause reactions from swelling to blood clots. Teva recently expanded that recall to 7 additional lots made at the plant in Gödöllő, Hungary, which the FDA put on its import alert this year.

In May, the Israel-based drugmaker recalled 14,370 units of divalproex sodium delayed-release tablets, which are used to treat certain types of epileptic seizures, as well as for bipolar disorder and migraines, after they failed unspecified specifications.

– check out the FDA enforcement report

thanks to: FiercePharma

Teva recalls antibiotic made at banned plant in Hungary


Teva headquarters 

When the FDA put Teva’s sterile manufacturing site in Hungary on its import alert list in May, it banned all but two of its products, cancer treatment bleomycin and antibiotic amikacin. The exclusions didn’t mean the FDA didn’t have some concerns with those drugs, and now the drugmaker is expanding a recall of the antibiotic.

Teva ($TEVA) said last week it was recalling 7 additional lots of amikacin sulfate due to the potential for the presence of glass particulate, which it said could cause reactions from swelling to blood clots. It said it had not received any reports of adverse reactions to the product.

When Teva first recalled a lot of the antibiotic in March, it indicated that it was manufactured at its plant in Gödöllő, Hungary. The company had temporarily halted production at the plant in January after an inspection cited it with a number of shortcomings. The agency followed that up with the ban in May.

After the FDA banned products from the Hungary plant, Teva said it was “working around the clock to restart manufacturing operations as soon as possible, and are working cooperatively with regulatory authorities to minimize any potential impact on product availability.”

That impact was particularly hard on Hungary, which lost access to about 200 drugs as a result of the shutdown. The Hungary drug regulator said it was getting weekly updates from Teva about the situation so that it could avoid shortages, particularly of cancer and morphine drugs.

– here’s the press release
– find the import alert here

thanks to: FiercePharma


Teva recalls seizure drug


Teva headquarters


Teva Pharmaceutical ($TEVA) has its hands full trying to finalize its $40.5 billion buyout of Allergan’s ($AGN) generics business, a deal it expects to close this week. But meanwhile business goes on as usual, and that involves a Teva recall of a seizure drug.

The Israel-based drugmaker is recalling 14,370 units of divalproex sodium delayed-release tablets after they failed unspecified specifications, according to the most recent FDA Enforcement Report. The drug is used to treat certain types of epileptic seizures, as well as for bipolar disorder and migraines. The recall, which was initiated in May, was identified last week by the FDA as a class III.

Teva has been working for more than a year to buy Actavis, the generic drug business of Allergan. Since Teva is already the world’s largest generics producer, the deal has received close scrutiny by regulators around the globe. The FTC said last week that it had approved the merger after Teva agreed to sell the rights and assets to 79 pharmaceutical products, which are being acquired by 11 different generic drugmakers.

Allergan’s generics business has had its own recalls to deal with this year. In February it said it was recalling 54 lots, consisting of nearly 600,000 bottles, of its copy of the ADHD drug Adderall.

– access the recall here

thanks to: FiercePharma

Teva pulls migraine patch Zecuity on reports of burning, scarring


So much for the $114 million Teva shelled out to get its hands on Zecuity developer NuPathe. After less than a year on the market, the Israeli drugmaker is pulling the migraine patch.

Monday, the company announced that it would stop sales, marketing and distribution of the product on post-marketing reports of burning and scarring at the patch application site. Teva has also launched a recall of the med from pharmacies.

The discontinuation follows an FDA alert on the drug from earlier this month that cited “severe redness, pain, skin discoloration, blistering, and cracked skin.”

“At Teva, the wellbeing of people using our products is always the first priority,” Teva CEO of global specialty meds Rob Koremans said in a statement, noting that the company would “continue our investigation into the root cause of these adverse skin reactions” and work closely with regulators to resolve any outstanding questions.

It’s a blow to the Petah Tikva-based generics giant, which nabbed NuPathe in 2014 in its quest to bulk up on the specialty side before Copaxone copies hit. And while that process took longer than industry-watchers expected–allowing Teva to switch the majority of patients over to a long-lasting, patent-protected formulation of its multiple sclerosis superstar–the therapy still took a hit last year, recording a 14% decline to $960 million and coming in shy of the billion-dollar tally analysts expected.

Meanwhile, Teva is also working hard to close the $40-billion deal for Allergan’s generics unit that it expects to solidify its No. 1 position in the generics space. After coming to terms on the acquisition last summer, the companies have been making divestments to satisfy antitrust regulators; Monday, India’s Dr. Reddy’s said it had agreed to pick up 8 drugs from Teva–including one already-marketed treatment–for $350 million.

– read Teva’s release

thanks to: FiercePharma



Teva halts production at sterile injectables plant to address FDA concerns


The FDA recently issued an import alert for all but two products at the facility in Gödöllő: cancer treatment bleomycin and antibiotic amikacin. The alert gives no insight into the nature of the problems, but a translated notice posted Friday by Hungary’s Food and Drug Administration (OGYE) says Teva suspended production four months ago as a precaution following an U.S. FDA inspection at the facility in late January.

Teva Pharmaceutical ($TEVA) in a statement today said that while it is unaware of any adverse reactions reported about products coming out of the facility, it decided to voluntarily stop production at the Gödöllő plant on a temporary basis while it evaluates and responds to the FDA’s concerns.

“We are working around the clock to restart manufacturing operations as soon as possible, and are working cooperatively with regulatory authorities to minimize any potential impact on product availability. We are also identifying alternative sources of supply, where needed. We are very conscious of unnecessarily triggering drug shortages and impacting patients while we focus on resolving regulatory concerns, as patients are always highest priority.”

The notice by the OGYE says the action has taken 200 Hungarian products out of production and the Hungarian agency has asked Teva for weekly updates so that it can avoid shortages, particularly of cancer and morphine drugs. Dr. Csilla Pozsgay, the director general of OGYE, said in the notice that “based on currently available information,  products on the market are safe–the FDA primarily objected to the production environment.”

Teva opened the $110 million, 15,000-square-meter (161,458-square-foot) plant in 2012. It said at the time that its 6 production lines were capable of producing between 160 million to 200 million units of injectable meds annually, mostly cancer meds, that were to be sold in 70 countries, primarily in the U.S., Europe and the Far East.

Other companies have been in the situation in which Teva now finds itself. The FDA last year cited three Mylan ($MYL) sterile injectable plants in India in a warning letter for a host of problems. Pfizer’s ($PFE) Hospira, which is the largest sterile injectables maker in the world, has had to deal with FDA concerns at several plants in the U.S., India and Italy.

– here’s the FDA import alert
– and the OGYE notice

thanks to: FiercePharma

Teva migraine patch gets close FDA scrutiny for causing burns and scarring


Seeking to offset early Copaxone sales declines, Teva swept up NuPathe a few years ago to get its hands on the only migraine patch approved in the U.S. But in less than a year after launch, the FDA has laid out concerns about “serious” adverse events including burning and scarring.

Teva’s Zecuity is now under the radar as a “large number” of users have reported those problems plus severe redness, pain, skin discoloration, blistering and cracked skin, the FDA reported. The patch first hit the market last September.

In a statement, a Teva spokesperson said the FDA’s decision was made “as a precautionary measure,” and that “there is nothing more important to us than the health and safety of those who use our products.”

“Patient wellbeing is at the heart of everything we do,” the statement said. “Teva is working closely with the FDA on the investigation.”

The development marks a headache for Teva, which bought Zecuity developer NuPathe in early 2014 for about $114 million, eclipsing Endo’s $105 million offer. At that time, the generics giant was looking to grow sales in the face of an earlier-than-expected patent loss for its megablockbuster multiple sclerosis drug Copaxone. That patent loss is still having repurcussions at the Israeli generics giant, with Q1 2016 results that fell short of expectations.

The investigation may also upset NuPathe investors, who stand to gain from tiered Zecuity sales milestones set up through the Teva deal.

Powered by a battery, Zecuity administers sumatriptan through a single-use device placed around a patient’s upper arm or thigh.

Though the patch has been FDA-approved since 2013 from NuPathe’s efforts, Teva didn’t get the product on the market in the U.S. until the second half of 2015. In promoting the product, the Israeli generics giant cited a study finding that Zecuity outperformed a nonmedicated patch in reducing headache pain and cutting light/sound sensitivity.

The FDA alert comes as Teva works to close a $41 billion deal to buy Allergan’s generics business, a price which some investors and investment bankers called into question this week because market dynamics have changed since the agreement.

– here’s the FDA alert

thanks to: FiercePharma

Teva retrieves amphetamines over impurity concerns


Teva Pharmaceutical ($TEVA) has its hands full already with its $40.5 billion deal to buy Actavis, the generics business of what is now Allergan ($AGN). But business goes on and that includes the occasional recall.

According to the FDA’s most recent Enforcement Report, Teva has added another lot, consisting of 9,717 bottles, to a recall of amphetamine tablets that were found to be highly out of spec for impurities during their last testing. The mixed salts product is made up of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate.

According to a letter Teva sent to customers, the voluntary recall began in November with the recall of two lots. It said there are no “safety concerns at the level observed.”

Teva CEO Erez Vigodman

The drugmaker had a couple of other significant recalls last year. It recalled three lots of fluoxetine, a generic version of the antidepressants Sarafem and Prozac, because of contamination. Those had been manufactured by its Croatia-based operating unit Pliva at a plant in Krakow, Poland. It also recalled 8 lots of its colon and rectal cancer injectable drug Adrucil (fluorouracil injection) after the drugmaker discovered that the lots might contain particles that it identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals.

The world’s largest generics maker struck a deal last year to buy the generics business of Allergan. Teva CEO Erez Vigodman told investors at the J.P. Morgan Healthcare Conference this month that the company’s focus this year will be on assimilating the new acquisition into its operations. The buyout comes even as the drugmaker has been significantly reducing its manufacturing operations to cut costs and improve margins.

thanks to: FiercePharma

Teva ‘s $520M bribery settlement with the feds sparks shareholder lawsuit

Justice statue with sword and scales
Teva is starting the new year facing a shareholder lawsuit after it last month paid $520 million to resolve bribery charges in Russia, Ukraine and Mexico.

Just after forking over $520 million to resolve federal bribery charges relating to its operations in Russia, Ukraine and Mexico, Teva is starting the new year facing a shareholder lawsuit.

Ra’bcca Technologies has filed a petition for approval for a derivative suit against Teva and several of its current and former officers, including ex-board members Chaim Hurvitz, Shlomo Yanai, Dan Suesskind, and former chairman Phillip Frost, Israel’s Globes news service reports.

Last month, Teva agreed to pay nearly $520 million to the U.S. Department of Justice and Securities and Exchange Commission to resolve violations of the Foreign Corrupt Practices Act. The criminal fine to the DOJ totaled more than $283 million, while Teva ponied up $236 million to the SEC.

“The respondents, past and present officeholders in Teva, bear responsibility for Teva’s act and failure in violating U.S. law, and should therefore compensate Teva for all the damages caused to it,” Ra’bcca representatives said, according to Globes.

In announcements detailing Teva’s admitted violations, U.S. authorities say company execs and employees in Russia bribed an official there to boost the government’s purchases of its multiple sclerosis med Copaxone.  The government official made $65 million between 2010 and 2012 setting up the purchases, even as Russia sought to cut costs on foreign drugs, prosecutors said.

Between 2001 and 2011 in Ukraine, Teva bribed a top official in order to “influence” the government’s decisions on Teva drug approvals, prosecutors said, providing the “registration consultant” with $200,000 monthly through a fee and other expenses.

And in Mexico, a Teva subsidiary’s employees bribed doctors to prescribe Copaxone since “at least 2005,” according to the U.S. government’s release. The company additionally admitted it didn’t have an adequate control system in place to catch the violations, and hired managers “who were unable or unwilling to enforce” existing policies, according to prosecutors.

Teva’s settlement—the largest fine paid by a pharma company over FCPA violations—comes after years of investigations into its practices. The company in November notified the Tel Aviv Stock Exchange that it had set aside $520 million to cover expected expenses for the violations. Early in 2015, after conducting its own investigation, the company said it had “likely” violated FCPA in a number of countries.

Along with paying the fines, Teva agreed to continue to work with the feds and to boost its internal compliance efforts. Prosecutors said the company received a 20% discount from the low end of sentencing guidelines due to its “substantial cooperation and remediation.”

The FCPA probe wasn’t Teva’s only legal entanglement, however. Among a number of generics makers, the company now faces a Justice Department probe into possible price collusion.

thanks to: FiercePharma


Ancient photos of Jerusalem


Jerusalem Südöstlicher Teil des Tempelplatzes. Links: Aķșā-Moschee, im Vordergrunde: Ķubbet eș Șachra (sogen. Omar-Moschee). 1915 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Südöstlicher Teil des Tempelplatzes. Links: Aķșā-Moschee, im Vordergrunde: Ķubbet eș Șachra (sogen. Omar-Moschee). 1915 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Südlicher und südöstlicher Teil der Altstadt von Nordost. 1915 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Südlicher und südöstlicher Teil der Altstadt von Nordost. 1915 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Westlicher Teil der Altstadt von Nordost. 1915 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Westlicher Teil der Altstadt von Nordost. 1915 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Nordwestlicher Teil des Tempelplatzes. 1915 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Nordwestlicher Teil des Tempelplatzes. 1915 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)


Jerusalem Aķșā-Moschee: Miḥrâb (Gebetsnische) erbaut von Saladin nach Rückeroberung der Stadt von den Kreuzfahren I, Jahre 1187 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Aķșā-Moschee: Miḥrâb (Gebetsnische) erbaut von Saladin nach Rückeroberung der Stadt von den Kreuzfahren I, Jahre 1187 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Aķșā-Moschee: Mimbar (Predigtkanzel). In Aleppo 1168 angefertigt, von Sultan Saladin für die Aķșā-Moschee gestiftet 1187 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Aķșā-Moschee: Mimbar (Predigtkanzel). In Aleppo 1168 angefertigt, von Sultan Saladin für die Aķșā-Moschee gestiftet 1187 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Inneres der Ķubbet eș Șachra (sog. Omar-Moschee) mit dem heiligen Felsen (17.5 : 13.5 m.). 1910 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939).

Jerusalem Inneres der Ķubbet eș Șachra (sog. Omar-Moschee) mit dem heiligen Felsen (17.5 : 13.5 m.). 1910 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939).

Jerusalem Inneres der Ķubbet eș Șachra (sog. Omar-Moschee) mit dem heiligen Felsen (17,5 : 13,5 m.). 1910 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Inneres der Ķubbet eș Șachra (sog. Omar-Moschee) mit dem heiligen Felsen (17,5 : 13,5 m.). 1910 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Ķubbet eș Șachra (Omar-Moschee): Kuppel 30 m. hoch, 20 m. im Durchmesser - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Ķubbet eș Șachra (Omar-Moschee): Kuppel 30 m. hoch, 20 m. im Durchmesser – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)

Jerusalem Ķubbet eș Șachra (Omar-Moschee): die Trommel der Kuppel mit den alten Mosaiken. 1910 - Bilder aus Palästina, Nord-Arabien und dem Sinai - Bernhard Moritz (1859–1939)

Jerusalem Ķubbet eș Șachra (Omar-Moschee): die Trommel der Kuppel mit den alten Mosaiken. 1910 – Bilder aus Palästina, Nord-Arabien und dem Sinai – Bernhard Moritz (1859–1939)


Ancient maps from Muslim civilization

We reveals 10 marvellous maps from Muslim Civilisation that include one of the earliest known maps of South Amercia and maps where the world appears upside down! A time when North was South and South was North, towards Mecca…

We tend to take many things for granted. Today, we are equipped with numerous means of communication and transport over land, sea and air. We have such freedom to swiftly travel around the globe, so much so that we tend to travel far and wide without ever considering the immense contributions others have made for our convenience. Great scholars from Muslim Civilisation, indeed, turned the world upside down with their maps; not just metaphorically but world maps once were literally upside down (with south dipicted at the top).

As more people began to travel the world 1,000 years ago for trade, exploration and religious reasons, the demand for good maps increased. Some of the world’s most precious maps were drawn then by scholars, geographers and seafarers who assembeld the geographical knowledge known to them – they carried out detailed mathematical analysis, measured and charted the Earth’s features, used sophisticated astrolabes to help assess height and distance – to construct intricate maps of the world. Here we introduce ten key examples.

Let the countdown begin!

10. Ali Macar Map 16th Century

The “Ali Macar Reis Atlas” is housed in the Topkapi Palace Museum Library (Hazine 644) in Istanbul. As a work of art, this atlas certainly ranks among the most successful. It consists of six portolan charts and one mappamundi, all on double pages, i.e., there are fourteen pages. They are drawn on parchment leaves and bound in leather, forming an appealing small volume.

The artist-cartographer who drew these charts must have been professionally connected to those who drew other similar maps in Christian Europe; and the artistic perfection of this atlas strongly argues against it being the isolated work of a captain who would only have been imitating such models; the author must have been a craftsman with great experience of this type of work.

9. Al Istakhri 10th Century

A world map by Abul Qasim Ubaidullah ibn Abdullah ibn Khurdad-bih al Istakhri (934 CE) aka Estakhri. The map is oriented with South at the top as was common of maps at the time. Picture displayed on “Old Manuscripts and Maps from Khorasan”. It was beilieved that Estakhri created the earliest known account of windmills. His Arabic language works included masalik al-mamalik “Traditions of Countries” and Suwar al-Aqaaleem “Shapes of the Climes”.

South Caucasus

From Al- Aqalim

Persian Gulf’s Coast

8. Tārih-i Hind-i Garbī Map 16th Century

The book entitled Tārih-i Hind-i Garbī (History of the West Indies), probably written by Muhammad b. Amir al-Suûdī al-Niksarī (d. 1591) in the 16th century, contains information about the geographical discoveries and the New World (America). This work, based on Spanish and Italian geographical sources, was presented to Sultan Murād III in 1573.

The book tells the amazing stories of the explorations and conquests of Columbus, Cortes, Pizarro, and others, and it also endeavours to incorporate the new geographic information into the body of Islamic knowledge. It presents a major effort by an Ottoman Muslim scholar, almost unique in the 16th century; firstly, to transmit through translation information from one culture (European Christendom) to another (Ottoman Islam), and secondly, to correct and expand Islamic geography and cartography.

7. Ibn Hawqal Map 10th Century

A map (also oriented with South at the top) by the widely travelled Abu al-Qasim Muhammad b. Hawqal, originally from al-Jazira region in Turkey, north of Mardin. He is also referred to as al-Nusaybini, after Nusaybin town located in the region.

Very little is known about Ibn Hawqal but he is believed to have been a Baghdad-based trader who loved traveling. Researchers attribute the dearth of information on Ibn Hawqal to the fact that he spent a substantial part of his life in traveling and never stayed put in a certain region. It is his book, Surat al-Ard, from which we can derive some information about him while to the effect that he was fond of reading especially books by Khurdadhebah, Qudadamah and al-Jihani, which might have been the reason behind his keenness to travel and see the places he read about.

6. Kâtib Çelebi Map 16th Century

Tuhfat Al-Kibâr fî Asfâr Al-Bihâr (The Gift to the Great Ones on Naval Campaigns) was written by Kâtib Çelebi in 1657 and emphasises the importance of the Turkish activities in the seas and the Ottoman contribution to the navigational history.

Kâtib Çelebi emphasised the importance of the science of geography at the introduction of Tuhfat al-kibâr and explained that the rulers of the state should know the frontiers and borders of the Ottoman State and the states in this region even if they do not know the whole of the Earth.

Çelebi valued history like we do in a modern sense today and asserted that most people did not know the real value of this branch of knowledge and thus viewed history as if it were a tale. He expressed his complaint about this saying “who reads and listens to a letter of love and faithfulness?”.

5. Al- Balkhī Map 9th Century

Persian geographer who was a disciple of al-Kindi and also the founder of the “Balkhī school” of terrestrial mapping in Baghdad. Picture displayed on “Old Manuscripts and Maps from Khorasan”.

4. Mahmud of Kashgar Map 11th Century

Mahmud of Kashgar completed his famous book Divânu Lügati’t-Türk in 1074. Famous for being a linguist, he wrote the book in order to teach Arab speakers Turkish and to prove that the Turkish language was as important as Arabic.

Mahmud stated that the regions of all the Turkish tribes from Europe to China were included in full detail within a circular map, which, as he pointed out, was drawn in order to indicate the regions the Turks inhabited.

The western, northern and southern parts of Asia were left undrawn but despite the fact that the map was full of errors, the data about the eastern regions were correct. Mahmud showed the Great Wall of China on his map and mentioned that this wall and high mountains acted as natural obstacles preventing him from learning the Chinese language. He also stated that Japan shared the same fate, being an island in the eastern part of Asia.

3. Book of Curiosities Map 11th Century

The Bodleian Library at the University of Oxford has purchased the medieval Arabic manuscript Kitab Gharaib al-Funun Wa-Mulah Al-Uyun popularised under the title the Book of Curiosities, an exceptionally rich text on cosmography. The treatise is one of the most important recent finds in the history of Islamic cartography in particular, and for the history of pre-modern cartography in general.

The manuscript, a highly illustrated treatise on astronomy and geography compiled by an unknown author between 1020 and 1050, contains an important and hitherto unknown series of colourful maps, giving unique insight into Islamic concepts of the world. The copy owned by the Bodleian library is the only nearly complete copy and the one to have been extensively studied and released in an electronic edition.

Mediterranean Sea

Indian Ocean

2. Piri Reis Map 16th Century

Piri Reis is a well known Ottoman-Turkish admiral, geographer and cartographer from the 16th century. His famous world map compiled in 1513 and discovered in 1929 at Topkapi Palace in Istanbul is the oldest known Turkish map showing the New World, and one of the oldest maps of America still in existence.

The half of the map which survives shows the western coasts of Europe and North Africa and the coast of Brazil with reasonable accuracy in addition to various Atlantic islands including the Azores and Canary Islands.





1. Al-Idrisi Map – The World Upside Down 12th century

one of the most famous maps from Muslim Civilisation. It was drawn by Muhammad al-Idrisi who was born in Ceuta (Morocco) in 1099-1100 CE, and died in 1166 CE. The map is oriented with South at the top as was common at the time

Al-Idrisi studied at Cordoba, and although he died in his birth place, he spent his working life at the Norman court of Palermo. At the age of 16, he travelled through Asia Minor, Morocco, Spain and the South of France and even visited England. His description of most of Western Europe is lively and, on the whole, quite accurate. The same is true of his treatment of the Balkans, whilst for the rest of Europe and for most of the Islamic world (with the exception of North Africa, with which he had a firsthand acquaintance) his account is based on the writings of others.

Al-Idrisi was a noteworthy and original geographer. He used in a creative way the system of cylindrical projection of the Earth’s surface, which was to be claimed some centuries later, in 1569, by the Flemish Gerard Mercator. Al-Idrisi’s other merit, according to Udovitch, is the extensive information he provides about contemporary Western Europe. Hitti also notes that Al-Idrisi’s map places the sources of the Nile-supposedly discovered in the latter part of the 19th century in the equatorial highlands of Africa…

Read More:

Sorgente: TOP 10 MAPS FROM MUSLIM CIVILISATION | Jack The Lad | Jack The Lad

Lawyer: Israeli authorities torture Palestinian minors during detention, interrogation

RAMALLAH (Ma’an) — Teenage Palestinians in Israeli prisons and detention centers say they have been tortured, verbally abused, kicked, and slapped by Israeli interrogators during detention and interrogation, according to a lawyer from the Palestinian Committee of Prisoners’ Affairs, who recently conducted a series of visits with Palestinian teens in Israeli custody.

Hiba Masalha’s collection of testimonies comes as the latest report amid years of well documented cases of abuse and mistreatment of Palestinian children by Israeli forces.
In a statement from the committee, Masalha quoted 15-year-old Muhammad Abd al-Hafith Atiyeh from the Issawiya neighborhood of occupied East Jerusalem as he recounted the night that “large numbers of Israeli troops and intelligence officers” arrived at his family home around 3 a.m. on April 19, and inspected the house before detaining him.
Some 31 other Palestinians, the majority of them minors, were detained the same night during mass raids in Issawiya, in a detention campaign that has continued to intensify in East Jerusalem neighborhoods as Israeli police crack down on Palestinian youth for alleged criminal offenses like rock throwing.
“After Israeli soldiers handcuffed and took me outside my home,” Atiyeh said, “they violently beat me with their hands, with clubs, with their rifles, and kicked me in the head, back, and abdomen.”
Atiyeh said he was then shoved inside a military jeep between two soldiers with his head down and “whenever I moved they slapped me in the face.”
He was then taken to Israel’s Russian Compound detention center where, according to Masalha, he was forced to “kneel with his face on the ground and his hands cuffed behind his back for 10 hours.”
Another teenage boy, Muhammad Arafat Ubeidat, 16, from the Jabal al-Mukabbir neighborhood of East Jerusalem, told Masalha that he was detained from his home on May, 19 at 3 p.m., after Israeli police and soldiers ransacked his house “messing up whatever they found on the ground.”
A commander then asked Ubeidat to sign a paper in Hebrew and Arabic certifying that “nobody had beaten him or assaulted him.”
After he signed the paper, the soldiers handcuffed him behind his back and took him to a military vehicle.
The teen was then sat between two soldiers with his head facing the ground for the duration of the ride, throughout which “the soldiers beat his back with their elbows and slapped his face repeatedly.”
Like Atiyeh, Ubeida was then taken to the Russian Compound detention center where he was interrogated for six hours until midnight, his hands and feet tied to a chair.
“An interrogator kept swearing at me and slapping my face the whole time telling me to admit to charges (I didn’t commit).”
Ubeida stayed 14 days in a cell at the compound, under no charge, during which he was subjected to 17 interrogation sessions.
Some days, he said, he had three or four interrogation sessions in one day. After the 14 days, he was then moved to Israel’s Megiddo prison.
Ubeidat pointed out that prisoners suffer severely when they have court hearings, as they have to travel from Megiddo prison in the north, to central Israel’s Ramla prison, then to Jerusalem, and back.
“The wardens who escorted us treated us very badly, beating us and swearing at us for no reason,” Ubeida said, “they denied us water and bathroom breaks during the long journey back and forth.”
Masalha reported similar experiences from Muhammad Hussein Halasi, 17, from Jabal al-Mukabbir, Omar Abu al-Foul, 17, from Jabaliya refugee camp in the Gaza Strip, Jihad Salih Ghaban, 17, from Beit Lahiya in the Gaza Strip, and residents of Shufat refugee camp in occupied East Jerusalem Yazan Nidal Issa and Nidal Majid Adwein.
The youth from the Gaza Strip were detained in April and May after they attempted to cross the border fence between Israel and the besieged coastal enclave without proper documentation, in attempt to go to Israel and look for work.
Masalha’s report came two days after the Palestinian Prisoner’s Society (PPS) released a statement saying Palestinians being held in Israel’s Etzion prison were subjected to assaults, while Israeli soldiers reportedly used electric shock on a 16-year-old prisoner. Defense for Children International – Palestine (DCIP) released a report last month describing the well documented abuse of Palestinians children by Israeli forces and the harsh interrogation practices used to force their confessions, which has long been the target of criticism by the international community.According to affidavits taken by DCIP for the report documenting the recent arrests and sentencing of Palestinian minors for rock throwing, two of the teenagers “both had maintained their innocence and confessed only after they had experienced physical and psychological abuse.”The youth described being kicked and punched while handcuffed, choked, and having a door slammed in their face.
Interrogations of Palestinian children can last up to 90 days according to prisoners’ rights group Addameer, during which in addition to being beaten and threatened, cases of sexual assault, and placement in solitary confinement to elicit confessions are also often reported, while confession documents they are forced to sign are in Hebrew — a language most Palestinian children do not speak.

According to the Palestinian Committee of Prisoners’ Affairs, Israeli forces have detained 560 children from occupied East Jerusalem alone since the beginning of 2016, and 110 minors were still being held in Israeli prisons, including four girls and 10 boys in juvenile detention centers.

Sorgente: Lawyer: Israeli authorities torture Palestinian minors during detention, interrogation

I gas tossici e la storia dell’Olocausto

IL GAS TOSSICO TEDESCO (19141944)Di Richard Widmann (2009)[1]

Quando il pubblico pensa all’argomento dello sviluppo e dell’utilizzo del gas tossico, da parte dei tedeschi e dei nazisti, nel corso degli anni precedenti e contemporanei alla seconda guerra mondiale, vengono subito in mente le immagini dei programmi di sterminio su vasta scala e delle camere a gas di Auschwitz e degli altri campi di concentramento. La storia dell’Olocausto tuttavia suggerisce che i nazisti utilizzarono metodi, attrezzature e gas che vennero messi all’opera per uno scopo diverso da quello per il quale erano stati progettati. Viene suggerito che, con delle modalità alquanto primitive, il personale dei vari campi di concentramento sviluppò metodi tra loro differenti per mettere all’opera quello che viene considerato un programma coordinato di sterminio degli ebrei.

La storia tradizionale dell’Olocausto suggerisce l’importanza dell’aver adattato attrezzature e metodi per mettere all’opera un programma di sterminio pianificato a livello centrale. Noi diremo invece che se la classe dirigente nazista avesse ideato un programma di sterminio degli ebrei, le armi di tale sterminio erano già sviluppate e avrebbero potuto essere utilizzate molto facilmente. L’apparato nazista per la guerra chimica era il più progredito del mondo. Il gas tossico prodotto durante gli anni che condussero alla seconda guerra mondiale rende assurda la storia tradizionale dell’Olocausto. Non c’è nessuna ragione per la quale i nazisti avrebbero avuto bisogno di modificare camion sovietici o di stornare l’utilizzo dello Zyklon B dai programmi di disinfestazione, concepiti per tenere in vita i detenuti, ai programmi di sterminio.[2] Le armi richieste per un programma di sterminio non solo esistevano ma erano fabbricate in quantità tale da poter attuare un programma del genere, se fosse stato ordinato.

L’utilizzo del gas velenoso durante la prima guerra mondiale

Per capire le potenzialità dei tedeschi riguardo ai gas tossici durante la seconda guerra mondiale, è importante esaminare brevemente l’utilizzo dei gas tossici durante la prima guerra mondiale. Durante la prima guerra mondiale, entrambe le parti del conflitto utilizzarono grandi quantità di gas tossico. Nel corso della guerra vennero utilizzate più di un milione e trecentomila tonnellate di sostanze chimiche, per agenti che andavano dal semplice gas lacrimogeno al gas mostarda.[3] Quando la guerra ebbe inizio, la Germania aveva la prima industria chimica di tutte le nazioni combattenti; in realtà, i tedeschi erano i leader del mondo intero. Le fabbriche di prodotti chimici più importanti erano situate nella Ruhr, ed erano conosciute come le Interessen Gemeinschaft Farben, o I. G. Farben.[4]

L’introduzione della guerra chimica venne attivamente sostenuta dalla I. G. Farben e dal suo capo, Carl Duisberg. Duisberg non solo esortò nel 1914, nel corso di una conferenza speciale, i vertici militari tedeschi a utilizzare il gas tossico, ma studiò personalmente la tossicità dei differenti gas bellici.[5] Duisberg sostenne anche Fritz Haber, principale scienziato dell’epoca, in Germania, e capo del suo laboratorio scientifico, l’Istituto Kaiser Wilhelm di Chimica Fisica a Berlino. Nei suoi studi sugli effetti del gas tossico, Haber notò che l’esposizione a una bassa concentrazione di gas tossico per lungo tempo aveva spesso lo stesso effetto (la morte) dell’esposizione ad un’alta concentrazione per breve tempo. Egli formulò una relazione matematica tra la concentrazione del gas e il tempo necessario di esposizione. Questa relazione divenne nota come regola di Haber.[6]

Durante la prima guerra mondiale, sia i tedeschi che gli Alleati utilizzarono in modo piuttosto efficace diversi tipi di gas tossico. Questi variarono dal cloro, all’inizio della guerra, al fosgene, che venne introdotto dalla I. G. Farben. Il fosgene era circa 18 volte più potente del cloro. Erano [già] mortali concentrazioni di 1/50.000.[7] Nel corso di questo periodo, i tedeschi svilupparono e inaugurarono diversi nuovi gas, per vedersi poi imitati dagli Alleati. Nel Luglio del 1917, la I. G. Farben creò un nuovo gas chiamato inizialmente dagli artiglieri “Croce Gialla”. La Croce Gialla era più letale di ogni altro gas precedente. Questo gas, il diclorodietilsolfuro, divenne noto come “gas mostarda”.

Le truppe che venivano attaccate con il gas mostarda, all’inizio accusavano solo una lieve irritazione agli occhi. Sembrava che facesse poco o nulla e molte truppe non si preoccupavano di mettere le maschere antigas. Ma nel giro di una giornata, subivano terribili sofferenze. I soldati sviluppavano sulla pelle macchie rosse e umide che si trasformavano in grandi pustole gialle che potevano raggiungere la lunghezza di un piede. Coloro che venivano colpiti dal gas mostarda morivano dopo una lunga agonia. Nel corso di dieci giorni, i tedeschi utilizzarono contro le postazioni alleate oltre un milione di proiettili contenenti 2.500 tonnellate di gas mostarda.[8] Per inciso, anche gli inglesi utilizzarono il gas mostarda negli ultimi giorni della guerra. In un attacco sferrato il 14 ottobre del 1918, Adolf Hitler venne momentaneamente accecato nel corso di una sortita inglese contro il 16° Reggimento della fanteria di riserva bavarese.[9]

Gli anni tra le due guerre

Negli anni successivi alla prima guerra mondiale, i principali combattenti annunciarono la propria opposizione all’utilizzo delle armi chimiche. A Ginevra, nel 1925, i rappresentanti delle maggiori potenze firmarono una restrizione legale contro l’utilizzo delle armi chimiche. Eppure, durante gli anni “interbellici”, varie nazioni europee utilizzarono di fatto il gas tossico. Tra loro vi furono gli inglesi (contro i sovietici nel 1919), gli italiani (contro gli etiopici nel 1935) e i giapponesi (contro i cinesi nel 1937).[10] Nel corso di questi anni la I. G. Farben continuò ad ampliare le proprie conoscenze scientifiche. Nei laboratori della Bayer, membro del cartello della I. G. Farben, uno scienziato, Gerhardt Schrader, fece una scoperta fondamentale. Il 23 Dicembre del 1936, egli mise a punto una nuova sostanza chimica nell’ambito di uno studio sui potenziali insetticidi. Durante l’esperimento, Schrader sperimentò il suo nuovo preparato sui pidocchi in una concentrazione di 1/200.000. Tutti i pidocchi morirono in pochi secondi.[11]

Nel Gennaio del 1937, Schrader scoprì che il suo nuovo prodotto aveva spiacevoli effetti collaterali sugli esseri umani. Il prodotto che Schrader aveva sviluppato era il Tabun, il primo gas nervino del mondo. Il Tabun rappresentava un balzo in avanti esponenziale nel livello di tossicità dei gas velenosi. Anche in dosi molto piccole, l’inalazione o l’assorbimento – attraverso la pelle – del Tabun colpiva il sistema nervoso centrale e provocava delle convulsioni e una morte quasi immediate.[12] Il Tabun era così letale che presto divenne chiaro che non poteva essere utilizzato come insetticida. Schrader, tuttavia, contattò il ministero della guerra e vennero effettuati degli esperimenti per conto della Wehrmacht.

Nel 1938, Schrader venne trasferito in una nuova sede per sviluppare nuovi preparati per la Wehrmacht. Egli scoprì ancora un altro preparato, a cui diede il nome di Sarin. Negli esperimenti iniziali del gas Sarin sugli animali, si scoprì che il Sarin era dieci volte più letale del Tabun.[13] Con l’approssimarsi della guerra, i chimici tedeschi vennero attivamente impiegati nello sviluppo del gas Soman. Il Soman, un altro preparato chimico organico della famiglia del Tabun, venne valutato come 200 volte più letale del Tabun.

Il gas tossico e la storia dell’Olocausto

Nonostante il livello di tossicità e le enormi scorte di questi mortiferi gas nervini, la storia dell’Olocausto si è sviluppata intorno all’utilizzo di due gas, il monossido di carbonio e lo Zyklon B. Lo Zyklon B venne sviluppato durante gli anni ’20, quando gli scienziati che lavoravano all’istituto di Fritz Haber svilupparono questo tipo di gas all’acido cianidrico per utilizzarlo come insetticida, specialmente come disinfettante per i magazzini di grano.[14] E’ interessante notare che la I. G. Farben vendette i diritti di produzione dello Zyklon B poco prima della guerra a due ditte private, la Tesch und Stabenow, di Amburgo, e la Degesch, di Dessau.

Secondo la detta storia, quattro dei sei principali “centri di sterminio” utilizzarono gas monossido di carbonio, che veniva presuntamente prodotto utilizzando mezzi alquanto disparati. A Chelmno, secondo Arno Mayer, I prigionieri venivano “ammucchiati in camion in cui finivano asfissiati dalle esalazioni del monossido di carbonio”. Egli prosegue osservando che “non c’era nulla di particolarmente moderno o industriale sia nelle installazioni che nelle operazioni condotte a Chelmno-Rzuchow”.[15]

Il secondo presunto centro di sterminio era Belzec. Quello che ci viene raccontato è che lì, dopo aver utilizzato monossido di carbonio imbottigliato, gli addetti allo sterminio passarono a utilizzare le esalazioni prodotte da camion.[16] A Sobibor, il gas sarebbe stato prodotto da un motore. Se dobbiamo credere a Kurt Gerstein, venne fornito lì, a scopo di sterminio, anche lo Zyklon B.[17] A volte leggiamo anche, sempre a proposito di Sobibor, del motore di un sottomarino utilizzato per produrre CO, per uccidere detenuti ebrei.[18] A Treblinka leggiamo del monossido di carbonio pompato in una camera dal tubo di scarico di un carrarmato catturato ai sovietici. La storia ortodossa dell’Olocausto contiene persino un episodio in cui il comandante di Auschwitz Rudolf Höss visita Treblinka e conclude che lì il metodo di sterminio è inefficiente.[19]

Si racconta poi che gli ultimi due “centri di sterminio”, Auschwitz e Majdanek, utilizzarono lo Zyklon B. Il processo di sterminio descritto per Auschwitz richiede che qualcuno salga su una scala sopra la “camera a gas”, apra il barattolo di Zyklon B con uno speciale apriscatole, e versi i granuli contenenti l’acido cianidrico in una speciale apertura della colonna di sostegno della camera nella quale i granuli avrebbero sviluppato il gas.[20] L’assurdità della storia riguardante le Zyklon B è che persino degli storici ortodossi dell’Olocausto come Jean-Claude Pressac e Robert Jan van Pelt hanno ammesso che le epidemie di tifo scoppiate nei campi richiedevano che ogni cosa venisse disinfestata, e che “c’era bisogno di tonnellate di Zyklon B per salvare [Auschwitz]”.[21] Così, prosegue la storia, da un lato i nazisti utilizzavano lo Zyklon B per disinfestare i campi, contrastando perciò la diffusione del tifo, e dall’altro utilizzavano lo stesso prodotto per uccidere gli stessi detenuti le cui vite stavano cercando di salvare.

La storia delle gasazioni dell’Olocausto suggerisce una mancanza di coordinazione, da parte del governo nazista. Vi sarebbe stata l’adozione simultanea di metodi diversi, che avrebbero prodotto risultati diversi per attuare quello che viene descritto in modo tipico come un “genocidio” industriale centralizzato. In realtà, la storia ufficiale dell’Olocausto suggerisce in sé stessa che il programma di sterminio fu tutt’altro che organizzato a livello centrale e che i metodi impiegati subirono sul campo un’evoluzione decisamente caotica.

Alla luce dello sviluppo di gas tossici sofisticati come il Tabun e il Sarin, e della loro produzione su vasta scala, la storia ufficiale dell’Olocausto appare assurda.[22] Gli storici dell’Olocausto devono ancora rispondere alla domanda del perché i nazisti non utilizzarono il Tabun o il Sarin se avessero voluto attuare uno sterminio degli ebrei. Inoltre, persino negli ultimi giorni della guerra, quando la classe dirigente nazista cercava nuovi armamenti sofisticati, non utilizzarono le loro scorte di gas tossico su nessun fronte. Tutto ciò si pone in totale contrasto rispetto all’immagine popolare che si ha dei metodi e della mentalità nazista.

Non vi sono dubbi che i sovietici scoprirono grosse quantità di Zyklon B quando giunsero a Auschwitz e a Majdanek, quantità che servivano a combattere il tifo piuttosto che a uccidere i detenuti. Similmente, i racconti dei motori dei sottomarini e dei carri armati catturati ai sovietici che emettevano le esalazioni diesel a scopo di sterminio appaiono essere nient’altro che un prodotto della propaganda di guerra. Se la classe dirigente nazista avesse voluto sterminare gli ebrei d’Europa, avrebbe avuto a disposizione mezzi molto più sofisticati e letali per attuare un tale piano. La storia ufficiale delle gasazioni dell’Olocausto richiede un’interruzione della ragione e una fede nell’assurdo.

[1] Traduzione di Andrea Carancini. Il testo originale è disponibile all’indirizzo:
[2] Jean-Claude Pressac e Robert Jan van Pelt, “The Machinery of Mass Murder at Auschwitz”, capitolo 8° di Anatomy of the Auschwitz Death Camp, Israel Gutman e Michael Berenbaum editori, Indiana University Press, Bloomington and Indianapolis, p. 215. Pressac e van Pelt raccontano l’incredibile storia delle SS naziste che avrebbero utilizzato il 95% di scorte di Zyklon B a scopo di disinfestazione per tenere in vita i detenuti, mentre avrebbero dirottato il rimanente 5% per azionare le presunte camere a gas in modo da uccidere la medesima popolazione carceraria.
[3] David Tchanz, “A Whiff of Death: Chemical Warfare in the World Wars” [Una zaffata di morte: la guerra chimica nelle guerre mondiali], Command, n°33, Marzo-Aprile 1995, XTR Corporation, San Luis Obispo, CA 93403, p. 48.
[4] L’impero dell’I. G. Farben.
[5] Tschanz, p. 49.
[7] Tschanz, p. 52.
[8] Tschanz, p. 53.
[9] William Moore, Gas Attack! Chemical Warfare 191518 and Afterwards [Attacco con il gas! La guerra chimica 1915-1918 e in seguito], Leo Cooper, New York, 1987, p. 223.
[10] Tschanz, pp. 54-55.
[11] Tschanz, p. 55.
[12] Ibidem.
[13] Ibidem.
[14] M. Szöllössi-Janze, “Pesticides and war: the case of Fritz Haber” [Gli insetticidi e la guerra: il caso di Fritz Haber], European Review, 2001.
[15] Arno J. Mayer, Why Did the Heavens Not Darken? TheFinal Solutionin History [Perchè i cieli non si oscurarono? La Soluzione Finale nella storia], Pantheon Books, New York, 1988, p. 391.
[16] Mayer, p. 402.
[17] Per un analisi approfondita del “Rapporto Gerstein” vedi:
[18] Friedrich Paul Berg, “The Diesel Gas Chambes: Myth Within a Myth”, Journal of Historical Review, Vol. 5, n°1, Inverno 1984, p. 23 [In rete all’indirizzo: .
[19] Raul Hilberg, The Destruction of the European Jews, Quadrangle Books, Chicago, 1967, p. 565.
[20] Pressac e van Pelt, p. 235.
[21] Ibid., p. 215.
[22] In una versione rielaborata del suo classico articolo sulle camere a gas a motore diesel, Friedrich Berg ha fatto esattamente questa affermazione. In effetti, ha dato un nuovo titolo al suo articolo: “The Diesel Gas Chambers: Ideal fort Torture – Absurdfor Murder” [La camera a gas a motore diesel: ideale per la tortura, assurda per l’omicidio], vedi Ernst Gauss, Dissecting the Holocaust [Esaminare l’Olocausto], Theses & Dissertation Press, 2000 (in rete all’indirizzo:

Sorgente: I gas tossici e la storia dell’Olocausto – Andrea Carancini

Leaked Audio of US Secretary of State John Kerry Shows Obama Wanted ISIS to Grow

Wikileaks released a leaked audio of US Secretary of State John Kerry’s meeting with members of the Syrian opposition, which is an evidence of Trump’s assertion that Obama was the founder of ISIS.

US Secretary of State John Kerry (Photo: Getty Images / AFP / Louisa Gouliamak)

On Wednesday, Wikileaks released new evidence of US President-elect Donals Trump’s assertion that Barack Obama was the founder of ISIS – a leaked audio of US Secretary of State John Kerry’s meeting with members of the Syrian opposition at the Dutch Mission of the UN on September 22. The audio also is an evidence of the fact that mainstream media colluded with the Obama’s administration in order to push the narrative for regime change in Syria, hiding the truth about arming and funding ISIS by the US, as it exposed a 35 minute conversation that was omitted by CNN.

Kerry admits that the primary goal of the Obama’s administration in Syria was regime change and the removal of Syrian President Bahar al-Assad, as well as that Washington didn’t calculate that Assad would turn to Russia for help.

In order to achieve this goal, the White House allowed the Islamic State (IS) terrorist group to rise. The Obama’s administration hoped that growing power of the IS in Syria would force Assad to search for a diplomatic solution on US terms, forcing him to cede power.

In its turn, in order to achieve these two goals, Washington intentionally armed members of the terrorist group and even attacked a Syrian government military convoy, trying to stop a strategic attack on the IS, killing 80 Syrian soldiers.

“And we know that this was growing, we were watching, we saw that DAESH [the IS] was growing in strength, and we thought Assad was threatened,” Kerry said during the meeting.

“(We) thought, however,” he continued to say, “We could probably manage that Assad might then negotiate, but instead of negotiating he got Putin to support him.”

“I lost the argument for use of force in Syria,” Kerry concluded.

According to Wikileaks, “the audio gives a glimpse into what goes on outside official meetings. Note that it represents the US narrative and not necessarily the entire true narrative.”

Earlier the audio was published by the New York Times and CNN, however, the both outlets chose only some its part, reporting on certain aspects, and omitted the most damning comments made by Kerry. In fact, they tried to hide the statements that would allow public to understand what has actually taken place in Syria.

The full audio has never been published by the New York Times; the outlet released only selected snippets. CNN deleted the audio at all, explaining this with the request of some of the participants out of concern for their personal safety.

Sorgente: Leaked Audio of US Secretary of State John Kerry Shows Obama Wanted ISIS to Grow

Parchi italiani: la nuova legge che fa paura a chi ama il verde


legge parchi

Legge sui parchi e le aree protette: una proposta di riforma alla precedente legge ancora in vigore (394/91) è stata approvata in Senato. Ma le modifiche introdotte, dalla gestione dei parchi e della fauna, alle norme sulle Aree Protette, sembrano impoverire molto il testo attualmente in vigore. Le proposte di modifica sono passate ora alla Camera, presso la quale si è svolta un’audizione per chiedere sostanziali modifiche al provvedimento.

Il testo era arrivato in aula il 21 ottobre, presentato dal senatore Massimo Caleo, e assegnato alla 13ª Commissione permanente (Territorio, ambiente, beni ambientali) in sede referente il 19 settembre 2013. Nonostante le proteste di associazioni ambientaliste, docenti ed esperti provenienti dal mondo della cultura, Palazzo Madama ha dato l’ok.

Federparchi fondamentalmente approva la riforma. Pur avendo infatti proposto alcune modifiche, giudica il testo un

lavoro indubbiamente migliorativo rispetto al passato, intorno al quale è importante trovare la più ampia convergenza.

Anche dal fronte agricolo plausi al testo. “La Cia-Agricoltori italiani  è sostanzialmente soddisfatta per l’approvazione al Senato del provvedimento sulle nuove disposizioni in materia di aree protette – ci ha scritto Dino Scanavino, Presidente della Confederazione Italiana Agricoltori – Infatti il testo votato riconosce finalmente il ruolo dell’agricoltura di qualità nell’economia dei Parchi, che è stata in questi 20 anni, di fatto, il principale alleato degli enti di gestione per garantire la tutela delle produzioni tipiche locali e un presidio di legalità”.

“La rappresentanza che verrà garantita all’interno dei nuovi consigli dei Parchi è un riconoscimento importante della funzione e dell’importanza che rivestono le aziende agricole sul territorio – ha continuato Scanavino – Ora auspichiamo in un iter veloce alla Camera per arrivare in tempi rapidi all’approvazione definitiva, con alcuni piccoli aggiustamenti utili nell’articolato, in particolare sulla questione “fauna selvatica” e sullo “snellimento burocratico”.

Perché però le associazioni ambientaliste sono insorte nuovamente considerando a voce quasi unanime il testo un pericoloso passo indietro rispetto alla legge attualmente in vigore?

Ecco i principali punti contestati.

Gestione e risorse

Il Presidente e il Direttore dei parchi potranno essere nominati senza competenze specifiche per la gestione, la conservazione e la valorizzazione dei beni naturali e ambientali, denuncia il WWF. Tra l’altro le Riserve Naturali dello Stato, anche quando sono comprese all’interno dei Parchi Nazionali, restano in capo al Ministero delle Politiche agricole, con un’evidente contraddizione gestionale, in quanto il Presidente dei parchi è una carica eletta dal Ministro dell’ambiente e della tutela del territorio e del mare.

Contestato inoltre il sistema gestionale complessivo. “Legambiente chiede l’abolizione dell’Albo dei Direttori dei Parchi – ci ha detto Rossella Muroni, Presidente di Legambiente, che abbiamo raggiunto al telefono – e l’apertura dei parchi a nuove generazioni, alla componente femminile, all’ingresso di nuove professionalità. I Parchi devono essere i luoghi dell’innovazione e di nuove soggettività che si mettono alla prova”.

“Nel nuovo DDL sui parchi manca quell’equilibrio necessario tra una dimensione nazionale dei parchi con l’altrettanto necessaria partecipazione delle comunità locali – ha continuato la MuroniCi vuole equilibrio, perché i parchi rispondono all’esigenza di difesa della natura che è innanzitutto dello Stato italiano. Questo vuol dire che naturalmente le comunità locali devono essere coinvolte a partire dai sindaci, dagli agricoltori, ma ci vuole una visione generale. Inoltre i parchi devono essere in grado di fare rete e devono avere certezze sul futuro”.

Preoccupa inoltre il silenzio sul potenziamento della sorveglianza e delle dotazioni organiche dei Parchi, considerate drammaticamente insufficienti.

“Il vero punto debole sono le riserve regionali, figlie di un dio minore, insieme alle Aree Marine Protette – ha sottolineato ancora la Presidente di Legambiente – Legambiente chiede un investimento certo pluriennale, perché Parchi Nazionali, Parchi Regionali e Aree Marine Protette costituiscono un ecosistema, un capitale naturale, che rappresenta non solo una ricchezza fondamentale in termini di biodiversità, ma anche la chiave di accesso a un futuro economico di sviluppo territoriale e di difesa del territorio (penso per esempio al rischio idrogeologico)”.

Mezzi motorizzati ed eliski nella Aree Protette

Ancora nessun divieto esplicito dell’uso dei sentieri da parte dei mezzi motorizzati e di pratica dell’eliski, sci fuoripista e del freeride che usano l’elicottero per la risalita e che rappresenta un’attività pericolosa per la fauna selvatica (su questo punto particolare accento è stato dato dal Club Alpino Italiano). Per le Aree Marine Protette, inoltre, non è previsto nessun ruolo di gestione per lo Stato.

“Nel tentativo di rendere più snella la Legge sulle Aree Naturali Protette, il Senato ha, di fatto, indebolito la portata ‘nazionale’ dei Parchi – ha detto alla Camera Donatella Bianchi, presidente del WWF Italia – accentuando l’influenza di interessi locali e logiche estranee alla corretta gestione del comune patrimonio naturale del Paese”.

parchi audizione1

Controllo della fauna

Gli abbattimenti potranno essere condotti anche da cacciatori previa frequentazione di corsi.

“Le “operazioni di controllo” della fauna, trattandosi di aree protette, dovrebbero essere ragionevolmente effettuate soltanto dal personale pubblico di sorveglianza e di polizia ambientale” ha tuonato Annamaria Procacci, Consigliere Nazionale Ente Nazionale Protezione Animali.

Inoltre dagli interventi non sono esclusi gli animali particolarmente protetti dalla legge nazionale di tutela della fauna. E non viene nemmeno considerato il disturbo venatorio che sarebbe causato su tutte le specie dall’uso delle armi, comprese quelle non oggetto di intervento cruento, nonostante l’Unione Europea ponga proprio il disturbo della caccia come uno dei fattori di più forte impatto sulla fauna.

parchi audizione2

Caccia nelle aree limitrofe

La riforma, in alcune parti, consente l’accesso dei cacciatori all’interno dei parchi e nelle aree contigue, le zone “cuscinetto” tra il parco e il territorio esterno. Attualmente possono cacciarvi solo i cacciatori residenti nell’area protetta, ma se passasse la riforma potrebbero farlo tutti gli iscritti agli Ambiti Territoriali di Caccia (ATC) in cui ricadono le aree contigue.

E, date le enormi estensioni degli ATC, vi sarebbero ricompresi i cacciatori di Comuni anche molto lontani dalle aree protette, persino provenienti da altre regioni. Inoltre gli animali che si riproducono all’interno delle aree protette diventerebbero facili prede dei cacciatori immediatamente a ridosso dei confini, dove è attualmente proibito cacciare.

“Si tratta di una proposta inaccettabile che abbiamo chiesto di rimuovere dal Progetto di Legge – ha commentato Massimo Vitturi, responsabile LAV area Animali SelvaticiAbbiamo inoltre richiesto che i Parchi diventino delle aree con specificità d’avanguardia, all’interno delle quali applicare il controllo, assolutamente non cruento,  della fertilità degli animali che vengono indicati come responsabili dei danni all’agricoltura”.

Finanziamento e apertura di nuovi parchi

Gli Enti Parco potranno essere finanziati da titolari di attività economiche all’interno delle aree naturali protette e nelle aree contigue con delle royalties. “É inaccettabile l’inserimento delle royalties, che esporrebbero, ovviamente, le zone più pregiate del nostro Paese a tante forme di sfruttamento a fini di bilancio, riducendo i beni naturali a una merce, come pure la fauna selvatica”, scrive l’Ente Nazionale Protezione Animali.

Inoltre potrebbe essere costituito un nuovo parco interregionale sul Delta del Po, decisione fortemente contestata in quanto la legge 394/91 escludeva esplicitamente la possibilità di due parchi nazionali e prevedeva, dopo il 31 dicembre 1993, l’istituzione di un Parco Nazionale.

“Noi chiediamo di non farlo – tuona Rossella Muroni – perché, per l’ennesima volta, si crea un’eccezione alla regola, mentre i parchi hanno bisogno di regole certe e di futuro”.

Roberta De Carolis

Sorgente: Parchi italiani: la nuova legge che fa paura a chi ama il verde

Il parroco di Scampia attacca Saviano: “Ci hai stancato, l’antimafia a tavolino non serve”



camorra-Redazione- Don Aniello Manganiello, già parroco di Scampia, contro Roberto Saviano.

“Riconosco a Saviano –dice il sacerdote- il merito di aver raccontato in modo sistematico e chiaro le attività criminali che infestano la Campania, ma ha sempre ignorato il bene che comunque esiste nelle nostre terre. L’opinione pubblica preferisce le storie che aumentano l’adrenalina, le trame violente e criminali. E lo scrittore preferisce ignorare gli uomini le donne che rischiano ogni giorno per contrastare la cultura mafiosa e il degrado del territorio napoletano”.

“Caro Saviano – continua il sacerdote- a Scampia ci sono stato come parroco e so di cosa parlo. Ti dico che non basta scrivere libri, fare antimafia a tavolino, ma occorre lottare per creare nuove condizioni di vita. Caro Saviano, siamo stanchi dei tuoi romanzi, delle produzioni cinematografiche e televisive. Siamo stanchi di Gomorra, vogliamo un’anticamorra delle opere. Anch’io sono stato minacciato di morte dai Lo Russo e ho rifiutato la scorta per stare in mezzo alla mia gente. Non chiedo altrettanto a Saviano, ma abbiamo bisogno di testimoni e non di maestri”


Sorgente: Il parroco di Scampia attacca Saviano: “Ci hai stancato, l’antimafia a tavolino non serve” – ArticoloTre | ArticoloTre – Quotidiano online indipendente e di inchiesta

Stefano Cucchi, “Lo pestarono: omicidio preterintenzionale per tre carabinieri” Procura di Roma chiude inchiesta bis

Arrestato, pestato a sangue dagli stessi carabinieri che lo fermarono e quindi deceduto in un letto d’ospedale. Otto anni dopo ecco che la procura di Roma contesta a tre militari l’omicidio preterintenzionale di Stefano Cucchi. Il procuratore capitolino Giuseppe Pignatone e il sostituto Giovanni Musarò hanno infatti chiuso l’inchiesta bis sulla morte del geometra romano, avvenuta in un reparto protetto dell’ospedale Pertini, il 22 ottobre 2009, sette giorni dopo il suo arresto nel parco degli Acquedotti.

I carabinieri che lo arrestarono – e cioè Alessio Di Bernardo, Raffaele D’Alessandro e Francesco Tedesco – sono ora ritenuti responsabili del pestaggio del giovane geometra. Ai tre  è contestata anche l’accusa di abuso di autorità, per aver sottoposto Cucchi “a misure di rigore non consentite dalla legge” con “l’aggravante di aver commesso il fatto per futili motivi, riconducibili alla resistenza di Cucchi al momento del foto-segnalamento“.

Le accuse di falso e calunnia nei confronti degli agenti di polizia penitenziaria processati nella prima inchiesta, sono invece contestate a vario titolo a Tedesco, a Vincenzo Nicolardi e al maresciallo Roberto Mandolini, comandante della stazione Appia, dove fu portato Cucchi dopo il suo arresto il 15 ottobre del 2009.

Cucchi – come si legge nell’avviso di chiusura delle indagini, atto che prelude alla richiesta di rinvio a giudizio – fu colpito a “schiaffi, pugni e calci“. Le botte, per l’accusa, provocarono “una rovinosa caduta con impatto al suolo in regione sacrale”, provocando sul giovane “lesioni personali che sarebbero state guaribili in almeno 180 giorni e in parte con esiti permanenti, ma che nel caso in specie, unitamente alla condotta omissiva dei sanitari che avevano in cura Cucchi presso la struttura protetta dell’ospedale Sandro Pertini, ne determinavano la morte“.

“Le lesioni procurate a Stefano Cucchi – si legge sempre nel provvedimento dei pm –  il quale fra le altre cose, durante la degenza presso l’ospedale Sandro Pertini subiva un notevole calo ponderale anche perché non si alimentava correttamente a causa e in ragione del trauma subito, ne cagionavano la morte”. “In particolare – scrivono i pm – la frattura scomposta” della vertebra “s4 e la conseguente lesione delle radici posteriori del nervo sacrale determinavano l’insorgenza di una vescica neurogenica, atonica, con conseguente difficoltà nell’urinare, con successiva abnorme acuta distensione vescicale per l’elevata ritenzione urinaria non correttamente drenata dal catetere”. Una quadro clinico che “accentuava la bradicardia giunzionale con conseguente aritmia mortale“.

Tedesco, Nicolardi e  Mandolini, invece, sono accusati di avere “affermato il falso in merito a quanto accaduto nella notte tra il 15 e il 16 del 2009 in occasione dell’arresto” di Cucchi. In particolare “implicitamente accusavano, sapendoli innocenti, tre agenti della penitenziaria, dei delitti di lesioni personali pluriaggravate e abuso di autorità”. Gli agenti della Penitenziaria erano accusati per un pestaggio che si “ipotizzava perpetrato – scrive il pm – ai danni di Cucchi nella mattina del 16 ottobre del 2009, nella qualità di agenti preposti alla gestione del servizio delle camere di sicurezza del tribunale adibite alla custodia temporanea degli arrestati in flagranza di reato in attesa dell’udienza di convalida”.

Il pm Musarò ha dunque ritenuto infondata l’ipotesi della morte per epilessia di Cucchi, emersa dalla perizia d’ufficio disposta dal giudice in sede di incidente probatorio. L’attacco epilettico del quale è stato vittima il giovane nei giorni di detenzione dopo il suo arresto, infatti, non figura tra le cause che ne hanno causato il decesso. Da qui il cambio di imputazione: i carabinieri ai quali viene ora contestato l’omicidio, infatti, sono stati a lungo indagati per lesioni personali aggravate, mentre i militari accusati di calunnia erano sospettati solo di falsa testimonianza. Uno di questi – il maresciallo Mandoliniera stato di recente promosso nonostante l’indagine in corso.

Inchiesta che adesso arriva a una svolta. Fino ad ora ben quattro giudizi avevano portato soltanto ad assoluzioni: confermate due volte in appello quelle per i sanitari dell’ospedale Pertini, diventate definitive, invece, quelle per gli agenti penitenziari che lavoravano nelle celle del tribunale di Roma.

“I carabinieri sono accusati di omicidio, calunnia e falso. Voglio dire a tutti che bisogna resistere, resistere, resistere. Ed avere fiducia nella giustizia”, commenta Ilaria Cucchi, sorella del giovane assassinato.  “Non lo so come sarà la strada che ci aspetta d’ora in avanti, sicuramente si parlerà finalmente della verità, ovvero di omicidio“, aggiunge la donna, che poi ringrazia l’avvocato Fabio Anselmo. “Ci sono voluti sette anni ma ce l’abbiamo fatta – dice invece il legale – Sono emozionato, felice. Credo sia un messaggio importante per tutti: quando si sa di essere dalla parte del giusto, bisogna resistere, resistere, resistere e la verità prima o poi viene fuori”. “La Procura ha esercitato una sua prerogativa e ha formulato il capo di imputazione che ritiene sussistente. Noi riteniamo, di contro, che tale contestazione non potrà essere provata nel giudizio in quanto gli elementi di fatto su cui fonda non sono riscontrabili in atti e, tanto meno, nella perizia disposta dal Gip con incidente probatorio”. dice l’avvocato Eugenio Pini, legale di uno dei carabinieri accusati di omicidio preterintenzionale. “L’attacco all’Arma è sotto gli occhi di tutti, nonostante le innumerevoli perizie stabiliscano con assoluta certezza che non ci sono state lesioni di alcun tipo che ne abbiano potuto procurare la morte (vedasi perizia disposta dal Gip), vengono cambiati i capi d’imputazione per non incorrere nella prescrizione e mandano a processo dei Carabinieri innocenti, dei padri di famiglia, dei Servitori dello Stato, solo per infangarli“, dice invece Mandolini, uno dei carabinieri indagati per falso e calunnia.

Sorgente: Stefano Cucchi, “Lo pestarono: omicidio preterintenzionale per tre carabinieri” Procura di Roma chiude inchiesta bis – Il Fatto Quotidiano

Libia, Alfano annuncia aiuti umanitari. Haftar rifiuta: ‘Prima via le vostre truppe’

“Rifiutiamo qualsiasi aiuto italiano a meno che l’Italia ritiri le sue truppe dalla Libia“. Lo ha dichiarato Khalifa al Obaidi, portavoce dell’esercito nazionale libico, guidato dal generale Khalifa Haftar, fedele al parlamento di Tobruk. Domenica scorsa, 15 gennaio, il ministro degli Esteri, Angelino Alfano, nel corso di un’intervista in tv aveva annunciato che l’Italia avrebbe inviato aiuti umanitari “medicinali […]

Sorgente: Libia, Alfano annuncia aiuti umanitari. Haftar rifiuta: ‘Prima via le vostre truppe’ – Il Fatto Quotidiano

The Israeli pharmaceutical giant Teva must pay over $520 million following corruption charges

Israeli drug firm fined for bribing officials in Russia, Ukraine & Mexico

A building belonging to generic drug producer Teva, Israel’s largest company with a market value of about $57 billion, is seen in Jerusalem. © Baz Ratner / Reuters

The Israeli pharmaceutical giant Teva must pay over $520 million following corruption charges made by the US Department of Justice (DOJ). The company breached the Foreign Corrupt Practices Act (FCPA) by bribing officials in Russia, Ukraine and Mexico.

Teva is the world’s largest manufacturer of generic pharmaceutical products. According to the DOJ, its fully-owned subsidiary Teva LLC (Teva Russia) bribed a top Russian official to increase sales of the multiple sclerosis drug, Copaxone, during drug purchase auctions held by the Russian Ministry of Health.

Between 2010 and at least 2012, Teva earned an extra $200 million from Copaxone sales in Russia. The Russian official allegedly received $65 million through inflated profit margins. His name and department were not disclosed.

Overall, Teva will pay $520 million which includes the US criminal and regulatory penalties for its illegal activity in Russia, Ukraine and Mexico.

In Ukraine, Teva hired a senior government official in the Ministry of Health as “registration consultant.” Between 2010 and 2011, the Israeli company paid him a monthly fee and covered his expenses, amounting to $200,000. In Mexico, Teva bribed doctors to prescribe Copaxone from at least 2005.

“Teva and its subsidiaries paid millions of dollars in bribes to government officials in various countries, and intentionally failed to implement a system of internal controls that would prevent bribery,” said Assistant Attorney General Caldwell.

“Companies that compete fairly, ethically and honestly deserve a level playing field, and we will continue to prosecute those who undermine that goal,” Caldwell added.

“As demonstrated by this case, the Foreign Corrupt Practices Act has a long reach. Teva’s egregious attempt to enrich themselves failed and they will now pay a tough penalty,” said William J. Maddalena, Assistan

thanks to: RT

UNSC passes resolution to end Israeli settlements

The United Nations Security Council (UNSC) has passed a resolution censuring Israel for its settlement activities in the occupied Palestinian territories after the US refused to veto it, reversing its longstanding policy of shielding the Israeli regime from condemnatory resolutions at the world body.

The Egyptian-drafted resolution was passed with 14 votes in favor and one abstention on Friday.

Egypt had withdrawn the measure after the Israeli regime asked US President-elect Donald Trump to pressure the North African country to delay voting on the draft resolution.

Israel, wary of indications that the US might veto the resolution, turned to Trump for support , who has defended Israel against condemnation for the settlement construction, and slammed the Obama administration for the “shameful move” against Tel Aviv.

It is the first resolution on Israel and the Palestinians that the 15-member body has passed in about eight years.

The Security Council was initially scheduled to vote on the resolution on Thursday.

However, on Friday, Malaysia, New Zealand, Senegal and Venezuela put forward the draft again, which called on Israel to “immediately and completely cease all settlement activities in the occupied Palestinian territory, including East Jerusalem” al-Quds.

It also said the construction of Israeli settlements has “no legal validity and constitutes a flagrant violation under international law.”

In this image released by the UN, US Ambassador to the UN Samantha Power (C) votes to abstain during the December 23, 2016 vote on Israeli settlements.

The vote possibly marks a short-lived turning point in US policy vis-à-vis the Israeli regime. Outgoing US President Barack Obama has said that the Israeli settlements pose an obstacle to the so-called Middle East peace process.

During the Friday session, US Ambassador to the UN Samantha Power told the council that the vote reflected the country’s complaints about Israel’s settlement construction.

“Our vote today is fully in line with the bipartisan history of how American presidents have approached both the issue and the role of this body,” she said, adding that settlement activity “harms the viability of a negotiated two-state outcome and erodes prospects for peace and stability in the region.”

‘Shameful resolution’

Infuriated at Washington’s abstention, Israel’s envoy lashed out at the Obama administration and expressed hope that both Trump and the incoming UN secretary general, António Guterres, would establish closer ties with Tel Aviv.

“It was to be expected that Israel’s greatest ally would act in accordance with the values that we share and that they would have vetoed this disgraceful resolution,” said Danny Danon.

“I have no doubt that the new US administration and the incoming UN secretary-general will usher in a new era in terms of the UN’s relationship with Israel,” Dannon added.

Meanwhile, the chief Palestinian negotiator and secretary general of the Palestine Liberation Organization, Saeb Erekat, hailed the UN vote as a “victory for the justice of the Palestinian cause,” while Israeli Prime Minister Benjamin Netanyahu voiced resentment.

Erekat said Trump now had to choose between “international legitimacy” or siding with “settlers and extremists.”

In a statement released on Friday, the Israel prime minister said it “rejects this shameful anti-Israel resolution at the UN and will not abide by its terms,” adding that Obama failed to “protect Israel”.

“Israel looks forward to working with President-elect Trump and with all our friends in [US] Congress, Republicans and Democrats alike, to negate the harmful effects of this absurd resolution,” the statement said.

Netanyahu’s office also announced in the early hours of Saturday that Tel Aviv had recalled its envoys to Senegal and New Zealand for consultations, and had tasked the Foreign Ministry with cancelling a scheduled visit to Israel by Senegalese Foreign Minister Mankeur Ndiaye and scrapping an aid program for the West African country.

Trump vows change at the UN

Shortly after the resolution was approved, Trump promised that Washington’s policies at the world body would “be different” during his administration.

“As to the UN, things will be different after Jan 20th,” he said in a tweet, referring to the date of his inauguration.

White House defends abstention

Dismissing Trump’s remarks, the White House on Friday defended its decision to allow the motion to pass at the UN, and reminded Trump that Obama was the US president until January 20.

“We could not in good conscience veto a resolution that expressed concerns about the very trends that are eroding the foundation for a two-state solution,” said Ben Rhodes, the White House deputy national security adviser.

In a statement released on Friday, US Secretary of State John Kerry said the UN resolution “rightly condemns violence and incitement and settlement activity and calls on both sides to take constructive steps to reverse current trends and advance the prospects for a two state solution.” He added, however, that Washington does not agree with every single aspect of the motion. 

The developments come more than a week after Trump announced his decision to nominate hardliner David Friedman as the US ambassador to Israel. Friedman is notorious for his fervent support of Israel’s illegal settlement expansion in the occupied territories, and has been characterized as an “obstacle to peace” by successive US administrations. He has said that he plans to work at “the US embassy in Israel’s eternal capital, Jerusalem.”

A picture taken on November 17, 2016 shows a general view of the illegal Israeli settlement of Ofra in the occupied West Bank, established in the vicinity of the Palestinian village of Beitin (background).

Earlier this month, Israeli lawmakers approved a hugely-controversial bill legalizing some 4,000 settler units built on private Palestinian land in the occupied West Bank, in the first of three readings needed to turn it into law.

The United States, Israel’s strongest ally, Germany, the country least critical of Tel Aviv in Europe, UN officials, and the European Union have strongly criticized the bill.

More than half a million Israelis live in over 230 illegal settlements built since the 1967 Israeli occupation of the West Bank and East Jerusalem al-Quds.

Built on occupied land, the settlements are internationally condemned as illegal and equal to land grab.

The Palestinian Authority wants the West Bank as part of a future independent Palestinians state, with East al-Quds as its capital.

thanks to: PressTV

La Coop e il Conad vendono datteri sporchi di sangue.

Con l’arrivo delle feste natalizie Coop e Conad hanno ripreso la vendita di datteri sporchi di sangue. Datteri provenienti dalle colonie israeliane illegali presenti in Cisgiordania, su terre rubate ai legittimi proprietari palestinesi, che sfruttano le risorse naturali e la manodopera palestinese, anche minorile.

Nonostante in passato Coop e Conad avessero deciso di non supportare l’apartheid israeliano sospendendo gli approvvigionamenti di merci prodotte nei territori occupati ma etichettate come prodotti di Israele, oggi apprendiamo da alcune nostre fonti che nei suddetti supermercati è possibile trovare ancora datteri illegali.

Datteri medjoul “Made in Israel” venduti presso la Unicoop Tirreno.

Datteri medjoul “Made in Israel” venduti presso la PAC 2000A.

In particolare presso la Unicoop Tirreno sono in vendita datteri medjoul di marca King Solomon e Jordan River distribuiti in Italia con marchio Fatina dalla Murano S.p.a. di Pomigliano d’Arco in provincia di Napoli, ma confezionati in Israele da Hadiklaim Date Growers LTD.

Datteri medjoul “Made in Israel” venduti presso la Unicoop Tirreno.

Datteri medjoul “Made in Israel” venduti presso la Unicoop Tirreno.

Hadiklaim è uno dei principali esportatori di datteri israeliani, prodotti in varie colonie illegali della Valle del Giordano, del Mar Morto e delle Alture del Golan.

Datteri medjoul “Made in Israel” venduti presso la Unicoop Tirreno.

L’importatore e distributore per l’Italia, la Murano S.p.a., ha aggiunto sulla scatola un adesivo con la dicitura ARDOC denominazione di origine controllata, che dovrebbe indicare la produzione dei datteri nella valle Arava a sud del mar Morto, in territorio israeliano. Ma non esiste alcuna D.O.C. denominazione di origine controllata di prodotti israeliani. Il termine è solo un modo per trarre in inganno l’acquirente visto che è utilizzato soltanto in Italia. Inoltre sull’etichetta è indicata la sede dell’impacchettamento ma non è possibile risalire a quella di coltivazione.

Dal 2015 è obbligatorio indicare sull’etichetta la provenienza dalle colonie israeliane dei prodotti agricoli. Decisione ribadita dall’Unione Europea nel 2016. Hadiklaim vende in Europa datteri confezionati in territorio israeliano per cercare di aggirare la normativa, la quale però prevede che gli stati membri applichino sanzioni efficaci, proporzionali e dissuasive per chi non indica l’esatta origine del prodotto.

Come mai la Unicoop Tirreno vende datteri che potrebbero provenire dalle colonie israeliane illegali e che tra l’altro violano la normativa UE sulla tracciabilità dei prodotti agricoli?

Datteri medjoul “Made in Israel” venduti presso la Unicoop Tirreno.

Ma non si comporta meglio Conad. Nei supermercati Conad aderenti alla PAC 2000A è possibile trovare in vendita datteri di qualità medjoul di provenienza israeliana con codice a barre italiano.

Datteri medjoul “Made in Israel” venduti presso la PAC 2000A.

Al Conad si possono trovare datteri ramati naturali distribuiti da Life S.r.l. di Sommariva Perno in provincia di Cuneo. Questi datteri di qualità medjoul sono importati da Israele senza indicare dove sono stati coltivati e nemmeno riportare quale azienda li ha esportati verso l’Italia, ma il codice a barre italiano che inizia per 800, li identifica come prodotto italiano.

Datteri medjoul “Made in Israel” venduti presso la PAC 2000A.

Addirittura la Noberasco S.p.a. di Albenga in provincia di Savona distribuisce presso Conad datteroni premium selection ovvero datteri di qualità medjoul che non solo riportano un codice a barre italiano ma che non indicano nemmeno il paese di importazione. Come se i datteri venissero coltivati in Italia. In realtà si tratta di datteri made in Israel come si evince dal loro sito internet.

Datteri medjoul “Made in Israel” venduti presso la PAC 2000A.

Datteri medjoul “Made in Israel” venduti presso la PAC 2000A.

Siccome Israele non fa distinzioni tra territorio israeliano e colonie israeliane illegali, come fa un acquirente del Conad a capire se questi datteri rispettano la normativa europea sulla tracciabilità dei prodotti agricoli provenienti dalle colonie israeliane illegali? Perchè la PAC 2000A vende datteri che potrebbero essere coltivati sulle terre che i coloni ebrei hanno rubato ai palestinesi?

Non sarebbe meglio evitare di proporre ai propri clienti prodotti così controversi visto che già in passato sia Coop che Conad si sono dimostrati contrari alla vendita di merci provenienti dalle colonie israeliane illegali?

Oppure se suddette catene di supermercati volessero a tutti i costi vendere datteri di qualità medjoul non sarebbe meglio importarli da aziende palestinesi certificate che non violano nessuna legge internazionale come quelle associate alla Ong PARC (Palestinian Agricultural Relief Committee)?

In attesa di qualche risposta inviamo i nostri più calorosi auguri di Buon Natale a tutti gli amici di Unicoop Tirreno e PAC 2000A. Che i datteri israeliani vi possano andare di traverso.

Boycott Israeli Dates


  • Israel is the world’s 3rd largest ($) exporter of dates worth $151 million in 2014.
  • The UK is Israel’s 3rd largest market for dates worth $23 million in 2014 (10,000 tons).
  • 60% of the world’s Medjool dates are produced in Israel (2013).
  • 60% of Israeli dates are grown on illegal settlement plantations in the Jordan Valley (2014).

If you buy a Medjool date, there’s a strong possibility that it is from an illegal settlement – grown on stolen land.

Boycott Israeli Dates leaflet (front)



Israeli settlements built on stolen Palestinian land have been ruled illegal by the International Court of Justice. Nearly half of the settlements in the Jordan Valley grow dates, it’s their most profitable crop, and contributes significantly to their economic viability. 80% of settlement dates are exported, making up some 40% of all dates exported from Israel. If you oppose the settlements then target their dates.

Palestinian child working in illegal Israeli settlement.
Out of desperate poverty Palestinian families are forced
to take their children out of school and hand them over
to the settlers to work for a pittance
(source: Channel4 news 7 July 2008)



Picking of the dates is hard work, Israeli settlers bring in low paid Palestinian labourers to do this back breaking work. During the pruning season, workers are dropped on the date palm trees by a hoisting crane at 5 in the morning, left perched on palms that soar to heights of 12 metres – a 4 storey building, left there swaying in the wind for up to 8 hours without even a toilet break, with no means to come down until the crane returns at the end of the day, the workers cling to the tree with one arm and work with the other to meet their quota. If they fall behind they will lose their jobs.


The Israelis prefer to employ children – even issuing them official work permits, as they can climb trees faster, work for less and it’s easier to cheat and humiliate them. Out of desperate poverty Palestinian families are forced to take their children out of school and hand them over to the settlers to work for a pittance.


Every year Israel expands its share of the global dates market – up 16% in 2011; up 23% in 2012, it surpassed Saudi Arabia to now become the world’s 3rd largest exporter of dates ($ terms) after Tunisia and Iran with an export value of $151 million in 2014. After the Netherlands and France, the UK is Israel’s largest market for dates worth $23 million in 2014 with nearly 10,000 tons of Israeli dates being exported to the UK.Hadiklaim, the Israeli Date Growers Cooperative, which includes illegal settler plantations in the Jordan Valley, sells 65% of all Israeli dates. Its brand names include Jordan River, King Solomon, Tamara Barhi Dates, Desert Diamond, Rapunzel, Bomaja, Shams and Delilah. They also supply Israeli dates to supermarkets who market them under their own brand. These include Marks & Spencer, Sainsbury’s, Tesco, Asda, Morrisons and Waitrose. Sometimes they are labelled “produced in the West Bank”, remember these are not Palestinian dates. Hadiklaim have also sold South African dates with profits going to Israel, but due to the boycott their South African partner Karsten Farms have cut ties and vowed never to partner with any Israeli entity complicit in the occupation.

Mehadrin, Israel’s largest fresh produce exporter, boasted of doubling their Medjoul date sales sighting strong demand in Ramadan! Their dates have brand names Premium Medjoul, Fancy Medjoul, Royal Treasure, Red Sea, and Bonbonierra. Sometimes their packaging states “Grown by Palestinian Farmers”, this refers to Palestinian ‘slave’ labourers found on Israeli plantations.

Tnuvot Field (Field Produce Marketing Ltd) is Israels 3rd largest exporter of Medjool dates. Its brand names include Paradise dates, and Star dates.


Unfortunately reading the label is no longer enough as Hadiklaim admit that from 2012 they have been shipping dates from the Jordan Valley labelled ‘Produce of Palestine’ to Europe and Dubai. It’s unclear how much of this is from Palestinian farms and how much is from illegal Israeli settlements.An Al-Jazeera report from August 2012 interviewed an Israeli agricultural export manager in Mahola settlement, one of the illegal Israeli colonies on the West Bank where Hadiklaim sources its Medjool dates. He explained a pallet of dates boxes in his packing warehouse labelled “Palestine – Jericho” by saying that “sometimes the British object [to buying from us].. We just avoid writing ‘Israel’ on the boxes.. we often print special boxes at the request of the client.. sometimes they ask us to change the name of the country of origin on the boxes.”

There are also reports of Palestinian ministry of economy intercepting 20 tons of Israeli settlement dates on their way to Palestinian packing houses for repackaging for export under the “Made in Palestine” label. Reporters from the Anadolu news in Sept 2014 interviewed several Palestinian merchants in Ariha involved in this nefarious activity. The collaborators admitted “We do trade in dates of the settlements, which we buy at prices that are 40 per cent lower than the market price. And in order to be able to market the dates, we clean and re-package them and choose the best in preparation for selling them in the local market, as well as the Arab and European markets” They estimate the annual volume of his seasonal sales of dates is nearly 350 tons. They use licensed companies that are registered officially. The export process takes place after the official bodies check the quality and specifications of the product, ensuring the product’s conformity with European specifications and international standards. It is then exported under the “Made in Palestine” label.

So now even the ‘Made in Palestine’ label is no longer a guarantee that you are not buying Israeli occupation dates! We would caution against buying any Medjool dates from the region unless they are from trusted Palestinian sources like Zaytoun or Yaffa.

Checking the label is not enough – label says Palestine – Jericho, but the dates are produced in illegal Israeli settlement of Mahola



In 2005 Palestinian civil society initiated a call for people of conscience around the world to Boycott, Divest and Sanction Israel until it complies with international law and Palestinian rights. The call was endorsed by over 170 Palestinian organisations representing all aspects of society including farmers.


Activists visiting the Palestinian village of Fasayl in the Jordan Valley discovered that villagers are slowly being forced off their land by the Israeli army for settlement expansion. The only livelihood left open to them is to work for those same Israeli settlements. These Palestinians whose land had been stolen and were forced to work for the settlements (including two children under the age of 12), in order to feed their families – they had a message for the activists, a plea for anyone who would listen – ‘take action against the companies that support Israeli apartheid!’ What excuse is left for us not to boycott Israel?

Help Us Distribute Boycott Israeli Dates Leaflets

Its simple – you don’t need to join any groups, just get a couple of friends together, order your free leaflets and start distributing!

With Ramadan rapidly approaching we need your help to get the message out to our people – Do Not Buy Israeli Dates. We need your help to distribute ‘Boycott Israeli Dates’ leaflets in your Mosques, your campuses, and your communities.

Its simple – you don’t need to join any organisations or facebook groups, just get a couple of friends together and order your leaflets. The leaflets are sent free of charge, just let us know how many you can distribute and we will send them.

This Ramadan don’t just think of the Palestinians, but act!

Our beloved Prophet (SAW) has said “The Ummah are like one body: if the eye is in pain then the whole body is in pain..”.

Today Palestine is bleeding…


Distributing on the internet

We also need your help creating awareness for the campaign on the internet, on social networking sites , etc. Included below are jpegs of the leaflet in various sizes so that you can start sharing them on your favourite websites, blogs, mailing lists, facebook and twitter.

Boycott Israeli Dates leaflet (1200px, both sides)

Boycott Israeli Dates leaflet (800px, back)



Educating Shopkeepers

When approaching shops that are selling Israel dates make sure you ask to speak to the owner – the person behind the till might just be a worker who has no say in what the shop sells. Always remember to be polite, remember you have the moral high ground so reason with them and give them a way forward without them loosing face.

Common responses from shop keepers and sample replies:

1. Everyone is selling them, why are you picking on my little corner shop, Tesco’s sells them why dont you go there?

There are campaigns all year around targeting supermarkets that sell Israeli goods. There has been a picket outside M&S for over 12 years now, we are not picking on you. If you know other stores selling Israeli dates let us know and we will also speak to them. Give the storeowner a leaflet – it includes logos of all the guilty supermarkets.

2. My customers ask for it. I also sell Tunisian dates, I provide choice – the customer decides, its a free country.

These dates are grown on stolen land, Palestinian families have been thrown off their land in order to grow these dates. If these dates contributed to YOUR families suffering, YOUR children’s suffering would you still sell them because customers ask for it? Is a Palestinian child worth less than YOUR child?

If your customers insist on Mejoul dates, why not order Palestinian Mejoul dates, these are now readily available in the UK from and

3. Everything is Israeli, it wont make any difference to boycott israeli dates.

Following a global boycott campaign Agrexco, Israel’s largest exporter of fresh produce which was half owned by the Israeli government actually went bust, our actions – ordinary people like you and me, can make a difference. The boycott helped end apartheid in South Africa and it can do the same in Palestine.

4. These dates are not Israeli, they are South African it says so on the box [ pointing to Kalahari Karsten Farms Mejoul dates box ]

Israel’s Hadiklaim cooperative which includes illegal settler plantation has struck a deal with Kartsen Farms in South Africa to market its dates in Europe, in this way the Israeli date company can supply dates through out the year, even when the Israeli date season is gone. Yes, whilst the dates are South African, but the profits still go to Israel, to those illegal settlement plantations, so please boycott them.

5. I do it for the Palestinians, I know that poor Palestinians are working on those Israeli farms. At least this was they will get a little money, so they dont starve over Ramadan.

When activists went to the Jordan valley and talked to these deprived Palestinian labourers who are forced to work for the Israeli settlements for their survival, some whose children as young as 12 years old were doing backbreaking work for the Israelis, they asked them what can we do to help? The reply was swift and unequivocal – the Palestinians urged them to take actions against these settlement companies that have taken their land and abused them – they asked us to boycott them. By buying those dates you are perpetuating this settlement ‘slavery’.


Sample letter to give shopkeepers

Dear Shopkeeper,Greeting of peace,Please spare a few minutes to read this important letter, thank you.

As a customer of yours I wish to draw your attention to something which is very dear to my heart and I am sure to many of your other customers and hopefully to yours as well, namely the plight of the Palestinian people.

For 60 years now they have lived under brutal Israeli occupation, their land stolen from them, their homes demolished and their children murdered in front of their eyes. The United Nations has condemned Israel on many, many occasions, and the International Court of Justice has ruled the Israeli settlements are illegal – built on stolen Palestinian land, and those that lived through the horror of apartheid in South Africa have described Israel as practising a much worse form of apartheid than anything they suffered under. And yet despite all this, the oppression continues, nothing changes.

So in 2005 Palestinian civil society, over a 170 organisations representing every aspect of society including farmers, teachers and labourers, issued a call asking ordinary people around the world, people on conscience like us – you and I, to help by respecting their call to boycott Israeli goods until Israel complies with international law and respects Palestinian rights.

It is in this endeavour that I humbly urge you, as your customer, please do not help oppress the Palestinians by selling Israeli goods, in particular please do not sell Israeli dates this Ramadan. Every year just before Ramadan, Israel especially targets small retailers who serve the Muslim community in to stocking its dates. The included leaflet lists which brands of dates are Israeli and should be avoided, it also includes details of the suffering Palestinians undergo in the production of these dates. This Ramadan please think of the Palestinians.

Thank you

PS As your customers, we will be frequenting your store, please do not disappoint – thank you


Boycott Israeli Dates leaflet (back)

DownloadBoycott Israeli Dates Leaflet (A5 300dpi ready-to-print PDF) (6Mb)
DownloadBoycott Israeli Dates Leaflet (A5 300dpi front JPG) (1Mb)
DownloadBoycott Israeli Dates Leaflet (A5 300dpi back JPG) (1.3Mb)


In 2004 the International Court of Justice ruled that the Israeli settlements are illegal – they are built on stolen Palestinian land. Growing dates is one of the major agricultural activities carried out by nearly half of the illegal Israeli settlements located in the Jordan Valley – it’s their most profitable crop , and contributes significantly to their economic viability.

Picking of the dates is hard work, so the Israeli settlers bring in Palestinian labourers to do this back breaking work. During the pruning season the workers are dropped on the date palm trees by a hoisting crane at 5 o’clock in the morning, left perched on palms that soar to a height of 10 or even 12 meters – the height of a three- or four-story building, left there swaying in the wind for up to 8 hours without a break and with no means to come down until the crane returns at the end of the day, the workers cling to the tree with one arm and work with the other to meet their quota. They can’t even take a break to go to the toilet. If they complain or fall behind their quota they will lose their jobs and their families will starve.

Palestinian child working in illegal Israeli settlement.
Out of desperate poverty Palestinian families are forced
to take their children out of school and hand them over
to the settlers to work for a pittance
(source: Channel4 news 7 July 2008)

But the Israelis prefer to employ children – even issuing them official work permits, as they are quick and light, can climb trees faster, work for less and it’s easier to cheat and humiliate them. Out of desperate poverty Palestinian families are forced to take their children out of school and hand them over to the settlers to work for a pittance.

Most of the Israeli date crop – up to 80%, is exported, mainly to Europe where it has around 10% market share. In 2005, dates were Israel’s leading fruit export.

The two major Israeli companies involved are Agrexco and Hadiklaim.

Agrexco, half owned by the Israeli government, handles 60-70% of all goods produced in the illegal Settlements. Its dates have brand names Carmel, Jordan Plains and Jordan Valley. Last September, a week before the start of Ramadan, Carmel boasted in their press release that they had managed an early crop of dates in order to meet the Ramadan demand for dates from Europe’s Muslims!

Hadiklaim sells 65 percent of the all dates produced in Israel. Its dates have brand names King Solomon and Jordan River. They also supply Israeli dates to supermarkets and retail chains who market them under their own brand names. These include Marks & Spencer’s, Sainsbury’s, Tesco’s, and Waitrose.

Sainsburys Medjool Dates
produced in the illegal Israeli settlement
of Netiv Hagdud in the West Bank

Sometimes they are labelled “produced in the West Bank” – this just confirms they are grown in the illegal Israeli settlements.

Peace activists who visited the Palestinian village of Fasayl in the Jordan Valley last year discovered that villagers are slowly being forced off their land by the Israeli army. The only livelihood left open to them is to work for Carmel Agrexco. The activists even spoke to two Palestinian children under the age of 12 who were working for Carmel. The Palestinian workers whose land had been stolen and were forced to work for Carmel in order to feed their families – they had a message for the peace activists, a plea for anyone who would listen – they urged them to take action against Carmel Agrexco and such companies that support Israeli apartheid. What excuse is left for us not to boycott Israel? If you oppose the illegal settlements target their dates. Boycotting can make a real difference.


Innovative Minds and the Islamic Human Rights Commission are calling on campaigners to create awareness in their communities about the boycott of Israeli goods, and in particular Israeli dates, this Ramadan.

In order to educate our communities on this issue two videos and a leaflet has been produced.

“Zaynab’s Story” explores the connection between an ordinary person living in Britain and what is happening in Palestine – how our actions as consumers in this country effects what happens to the Palestinians. It’s a heart wrenching video which exposes the brutality of the occupation as it touches the lives of ordinary people in Palestine. It then traces exactly how our buying habits help sustain this occupation, and ends by exploring ways in which we can start supporting the Palestinians. The boycott of Israeli dates forms its central theme. Its premier both in this country and overseas has been very well received. It duration is 36 minutes, and its available both as a DVD, or as a downloadable AVI for screening in a mosque, community centre or student society, and as streaming video on Youtube for personal viewing.



DownloadZaynab’s Story Video (480×360,700kbps AVI) (221Mb)

“Boycott Israeli Dates” was specifically created for screening at venues with time restrictions which would not permit the screening of “Zaynab’s Story”. It duration is only 18 minutes, and concentrates solely on the boycott of Israeli dates. It is available both for downloading (hi-res AVI) or streaming (low-res Youtube).

Please help us reach the widest possible audience by making copies of the videos, DVDs and passing them to your friends, placing them on your websites, etc.


Boycott Israeli dates leaflets can be obtained by contacting the Islamic Human Rights Commission on 02089040222. Alternatively the original PDFs used for printing the leaflets are available for download should you wish to do your own printing ( rough guide to printing cost in the UK: 10,000 leaflets £125 inc delivery ).

Boycott Israeli Dates leaflet (front)

Boycott Israeli Dates leaflet (back)

DownloadBoycott Israeli Dates Leaflet (A5 ready-to-print PDF) (5Mb)We have also produced a sample letter to give to local grocery shops, greengrocers, etc. that serve the Muslim community. The letter politely asks the the shopkeeper not stock Israeli dates this Ramadan. Only one letter, with perhaps 3-6 people signing it, needs to be given to each shop (along with a leaflet which identifies the brands to avoid).

Dear Shopkeeper,Greeting of peace,Please spare a few minutes to read this important letter, thank you.

As a customer of yours I wish to draw your attention to something which is very dear to my heart and I am sure to many of your other customers and hopefully to yours as well, namely the plight of the Palestinian people.

For 60 years now they have lived under brutal Israeli occupation, their land stolen from them, their homes demolished and their children murdered in front of their eyes. The United Nations has condemned Israel on many, many occasions, and the International Court of Justice has ruled the Israeli settlements are illegal – built on stolen Palestinian land, and those that lived through the horror of apartheid in South Africa have described Israel as practising a much worse form of apartheid than thing they suffered under. And yet despite all this, the oppression continues, nothing changes.

It is now left for us ordinary people to put pressure on Israel by boycotting its goods, by boycotting the fruits and vegetables it grows on land stolen from the Palestinians. It is in this endeavour that I humbly urge you, as your customer, please do not help oppress the Palestinians by selling Israeli goods, in particular please do not sell Israeli dates this Ramadan. Every year just before Ramadan, Israel especially targets small retailers who serve the Muslim community in to stocking its dates. The included leaflet lists which brands of dates are Israeli and should be avoided, it also includes details of the suffering Palestinians undergo in the production of these dates. This Ramadan please think of the Palestinians.

Thank you

DownloadSample letter to shopkeepers (Word DOC) (100Kb)
The idea is for activists to arrange a Boycott Israel awareness event in their community where they show one of the videos, give out the leaflets and ask people to sign the letters addressed to local shops serving the community (print out only one letter per shop which everyone signs like a petition).

If you do initiate a Boycott Israeli Dates campaign in your community please do contact us via the feedback form (on the left column of this page) and share your experience with us.

This Ramadan there is no excuse for any Muslim in the world to open their fast with an Israeli date.

Sorgente: Boycott Israeli Dates Campaign